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Abstract 
uterine sarcoma is a relatively uncommon group of tumors which account for 
4-9% of all uterine malignancy. Its rarity and aggressive behaviors make treatment of 
uterine sarcoma a challenging topic. The use of cytotoxic chemotherapeutic drug, 
Doxorubicin (Dox) was the primary treatment for uterine sarcoma. However, the use 
of anti-cancer drug often leads to the development of multidrug resistance (MDR) 
which reduces the effectiveness of chemotherapies. It is important to clarify the 
genes related to the development of MDR； such that the therapeutic effect of 
chemotherapy can be improved. Recently, many researches analyzing the gene 
expression profile of MDR have been carried out. 
In this study, the Dox-sensitive human uterine sarcoma cell line, namely SA cell 
line, and its multidrug resistant counterpart DX5 cell line were used as cellular 
models. By Methylthiazoletetrazolium (MTT) assay, it was found that DX5 cells were 
more resistant to Dox than SA cells. It was found to be due to the higher expression 
and activity of P-glycoprotein in DX5 cells than that in SA cells. 
According to previous microarray results performed by our laboratory； it was 
supposed that Ninjurinl (Ninjl) and Thrombospondinl (THBSl) play a role in cancer 
‘ ( 
progression and maintenance of MDR in human hepatocellular carcinoma. To 
examine whether same situation may appear in other human cancers, the expression 
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of multidrug resistant gene MDRl, as well as Ninjl and THBSl were verified at the 
mRNA and protein levels in SA and DX5 cells. Our results in present study indicated 
that Ninjl and THBSl were down-regulated in DX5 cells, accompanied by the 
over-expression of MDRl. 
To verify the relationship between Ninjl and THBSl, and MDRl, transfection of 
Ninjl and THBSl was done on DX5 cells to reverse their down-regulation in DX5 cells. 
It was found that the mRNA level of MDRl in the THBSl- transfected DX5 cells was 
lower than that of the control. The protein level of P-glycoprotein was reduced in 
response to Ninjl and THBSl over-expression. By flow cytometry, it was also found 
that the Dox uptake level of both Ninjl-transfected DX5 cells and THBSl-transfected 
DX5 cells were higher than that of the control. Consistent results were shown in MTT 
assay that the Ninjl-transfected DX5 cells and THBSl-transfected DX5 cells were 
more sensitive to Dox treatment than the DX5 control cells. The results of the 
present study collectively suggested that the over-expression of THBSl and Ninjl 
would down-regulate the expression of P-glycoprotein and thus increase the 
sensitivity to Dox in DX5 cells. Thus； the role of Ninjurinl and Thrombospondinl in 
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1.1 Clinical management of Cancer 
Cancer has been a leading cause of death in recent decades. According to the 
GLOBOCAN 2008 estimates, there were about 12.7 million cancer cases and 7.6 
million cancer deaths in 2008； and the number keeps rising rapidly. The major types 
of cancer contributing to the overall mortality were lung, colorectal, liver and breast 
cancer. 
I. Carcinogenesis 
Cancer refers to a class of disease characterized by uncontrolled proliferation of 
cells with the ability in metastasis. The transformation of normal cells into malignant 
cells involves a multi-step process of cellular function disorder, in which the crucial 
steps are that the cells are self-sufficient in growth signals or irresponsive to growth 
inhibitory signals (Hanahan et al. 2000). The alternation in cell behavior was related 
to gene mutation. There are mainly two types of genes in carcinogenesis, namely 
oncogenes and tumor suppressor genes, which are often relating to cell growth 
regulation and differentiation. The activation or over-expression of oncogenes and 
the repression of functional tumor suppressor genes cause failure in inhibiting 
f 
division and survival of normal cells. Thus, malignant cells are formed. 
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II. Cancer Classification 
Cancer is classified according to the type of tissue in which the cancer originates 
or the location in the body where the cancer first developed. With reference to the 
International Classification of Diseases for Oncology (third edition), cancer is grouped 
into six major categories: carcinoma； sarcoma； myeloma, leukemia, lymphoma and 
mixed types. 
Carcinoma refers to the malignant cells originated from the epithelial tissues or 
cancer of the external or internal lining. It can be further classified into two subtypes: 
adenocarcinoma, which develops in an organ or gland, and squamous cell carcinoma, 
which grows in the squamous epithelium. Carcinoma is the major type of cancer 
which contributes to about 80 to 90 percent of all cancer cases. Sarcoma refers to 
the cancer originated in supportive and connective tissues, such as bone, muscle and 
fat. Myeloma refers to the cancer which originates in the plasma cells of bone 
marrow, which are the cells responsible for antibody production. Leukemia refers to 
the cancer originated in bone marrow and leads to the overproduction of immature 
white blood cells. Lymphoma refers to the cancer which originated in the glands or 
nodes of the lymphatic system. It can be subclassified into two subtypes: Hodgkin 
lymphoma and Non-hodgkin lymphoma. Mixed types cancer refers to the 
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combination of cancer cells within one category or from different categories. The 
examples are adenosquamous carcinoma, carcinosarcoma, teratocarcinoma, etc. 
III. Cancer treatment 
With better understanding of cancer in the molecular level； many novel cancer 
treatments have been developed in the past decades, including target therapies and 
photodynamic therapy (Ma et al. 2009) 
Target therapies include the use of monoclonal antibodies and small molecule 
inhibitors. With distinct mechanism of action and toxicities, the target therapy agents 
are more effective in treating cancer with specific molecular target (Gerber et al. 
2008).Monoclonal antibodies work by recruiting the host immune function, binding 
to ligands or receptors which interrupts cellular process and carrying a lethal payload 
to the targeted cancer cells (Adam et al. 2005). Small molecular inhibitors are 
chemically manufactured molecules that target at interrupting cellular process, such 
as interfering the intracellular signaling of tyrosine kinase or apoptotic pathway 
(Gerber et al. 2008; Ghobrial et al. 2011). 
I 
Photodynamic therapy (PDT) made use of visible light and photosensitized 
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agents, i.e. photosensitizers. Upon visible light irradiation on the photosensitizers 
accumulated in the cancer cells, reactive oxygen species will be generated and cause 
cell death (Huang et al. 2005). 
Despite the development of novel cancer treatment, the conventional cancer 
treatments are still the major method of getting rid of cancer cells. The conventional 
cancer treatments include surgery； radiation therapy； hormonal therapy and 
chemotherapy. 
In surgery, the tumor and the surrounding tissues and lymph nodes are excised 
physically. However； it is not applicable for metastasized tumors and liquid tumors. 
In radiotherapy, the tumor is killed directly or tumor cells proliferation is 
suppressed by high-penetrating radiation. However, it might cause DNA damage or 
ionization of cellular molecules in the surrounding cells due to the high energy. 
In hormonal therapy, exogenous hormone analogues or enzyme inhibitors were 
used to block the hormone production pathway； such that the growth of cancer cells 
can be inhibited. However, it is only applicable for hormone-sensitive cancer. 
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In chemotherapy； toxic drugs were used in killing cancer cells. It is applicable for 
metastasized and liquid cancer. The most commonly used chemotherapeutic drugs 
are: Taxol (Paclitaxel), Methotrexate (MTX) and Doxorubicin (Dox). Taxol binds 
specifically to the y5-subunit in the microtubule. This hinders the transport or 
cellular components and cytoskeleton restructuring during cell division (Orr et al. 
2003). Methotrexate (MTX) inhibits dihydrofolate reductase (DHFR) which interferes 
with the folate metabolism for purine and nucleoside thymidine synthesis which are 
needed in DNA sythnesis (Bertino et al. 1996). Doxorubicin (Dox) is a DNA 
intercalating agent (Fornari et al. 1994). Although chemotherapy has been effective 
in killing cancer cells, it causes a number of side effects, including nausea, reduction 
of appetite, hair loss and destruction of other normal cells. Among those side effects； 
the development of multidrug resistance due to prolong exposure to certain drug 
becomes the major obstacle of chemotherapy. As the major focus of present study, 
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Figure 1.1 Chemical structure of Doxorubicin 
Doxorubicin is the chemotherapeutic drug used in the present study. It has been 
shown potent for a wide variety of cancer over the past decades. Doxorubicin (Dox) is 
a DNA intercalating agent. It binds to the DNA-topoisomerase II complex when the 
DNA is unwound. This inhibits replication and macromolecular synthesis of cells 
(Fornari et al. 1994). However, there are two limitations on the use of this drug in 
cancerous treatment. 
Firstly, cumulative dose of Doxorubicin is proven to be leading to myocardial 
dysfunction (Olson et al. 2003). It is believed that the Dox-derived semiquinone free 
radicals caused the acute cardiac injury or chronic heart failure in dose-dependent 
manner (Gilleron et al. 2009). 
Moreover； Doxorubicin is a substrate of an ATP-binding efflux pump 
P-glycoprotein, which is encoded by the gene mdrl. It has been proven that 
prolonged exposure of tumor cells to doxorubicin would lead to the upregulation of 
mdrl gene and lower the drug sensitivity of cells (Hui et al. 2008). 
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1.2 Multidrug resistance 
Multidrug resistance (MDR) refers to the phenomenon that enables a tumor cell 
to resist a wide range of drugs differing in chemical structure and functioning 
mechanisms. The tumor cells developing into MDR will be protected from damage 
and programmed cell death, so that the cells proliferate uncontrollably. MDR can be 
an intrinsic nature of a tumor cell, but it is often built from nature selection of cells 
towards prolonged drug treatment. It takes an important role in chemotherapy 
failure. Therefore； researches are done extensively in multidrug resistance so as to 
tackle it and increase the effectiveness of treatment. 
There are several revealed mechanisms concerning multidrug resistance, which 
targets at different stage of chemotherapy. The mechanisms include (l)increased 
efflux of drug； (2)drug detoxification, (3)alteration in drug target and (4)alteration in 
drug-induced apoptosis (Stavrovskaya et al. 1999; Krishna et al. 2000) 
I. Increased efflux of drug 
The efflux of drug is highly related to the ATP-binding cassette (ABC) transporters 
superfamily. These transporters have a well-preserved homology of the site where 
ATP binds. The drugs intaken are pumped out from the membrane biiayer to the 
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exterior driven by the energy from ATP hydrolysis. There were 48 ABC genes reported 
in human, and among those genes, 14 of them have been reported relating to 
human diseases. Some of them have been reported up-regulated in drug-resistant 
malignant cells, so that the sensitivity of the cancerous cells towards cytotoxic drug 
treatment is lowered. The ABC transporter proteins involving in cancer include 
Multidrug resistance-associated protein (MRP), breast cancer resistance proteins 
(BCRP) and the most well-know P-glycoprotein (Pgp). They are responsible for 
pumping a wide range of substrates specifically as listed in figure 1.2. Some of the 
these transporter proteins were expressed intrinsically for removal of metabolic 
waste, whereas some of them only exist as gene but not expressing, the gene 
expression is initiated upon exposure to anticancer drugs (Choi et al. 2005). 
Multidrug resistance-associated protein (MRP) is an asymmetrical molecule with 
eight subunits and four transmembrane domains. It is also called GS-X pump, which 
needs glutathione. It is the transporter of glutathione conjugates, which is important 
for maintaining normal life of cells and plays a role in inflammation. It was found to 
be expressed at basal level in many tissues including lung, bladder and adrenal 
* 
glands. However； it was found that the MRP expression is much higher in drug 
resistant cells of acute myeloid leukemia (Broxterman et al. 1997) and lung cancer 
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(Giaccone et al.l996). 
P-glycoprotein (Pgp) was encoded from MDRl gene. It is a large plasmid 
membrane protein with molecular weight of 170kD. It consists of two similar halves 
each containing six hydrophobic transmembrane domains and two ATP-binding 
domains. The P-glycoprotein interacts directly with drug molecule through a specific 
binding site which is located in the transmembrane domains or directly under the 
membrane. It was shown that P-glycoprotein interacts with a wider range of drug 
molecules than MRPs. Therefore, it is more related to cross-resistance of drugs. 
P-glycoprotein is expressed differently in different tissues, such as skin, lung, 
and kidney. There is high expression of P-glycoprotein in stem cells and early 
progenitors in normal bone marrow, but the expression and activity of it reduce 
gradually upon differentiation. P-glycoprotein is also expressed intrinsically for 
protection of cells from toxic injury. For example, it is expressed in the blood-brain 
barrier and in the cavity of colon (Stavrpvskaya et al. 1999). 
However, the high inducibility of MDRl/Pgp makes it easier for the tumor to 
develop into multidrug resistance. Multidrug resistance occurs when there is higher 
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expression of MDRl gene, higher stability of MDRl mRNA, and higher P-glycoprotein 
activity. It was found that the higher transcription level of MDRl gene can be induced 
by molecules other than its own substrate or even irradiation; while the activity of 
P-glycoprotein can be induced by heat shock and a wide variety of inducer depending 
on the particular condition. The expression of active P-glycoprotein depends on the 
type of the cells from which the tumor arises. The overexpression of P-glycoprotein is 
often found after tumor therapy. This plays a significant role in acquirirrg multidrug 
resistance and chemotherapy failure (Lage et al. 2008). 
To tackle the lowered drug sensitivity of tumor cells due to high expression of 
P-glycoprotein； there are several modulators developed to overcome Pgp-MDR. The 
compounds are calcium channel blockers (such as verapamil)； hypotensive drugs, 
antibiotics； immunosuppressors (such as cyclosporine A) and lipophilic compounds. 
These compounds effectively increase the drug sensitivities of tumor cells, but also 
cause toxicity to normal cells and the effect would be declined depending on the life 
span of modulators (Stavrpvskaya et al. 1999). 
II. Drug detoxification 
Drug detoxification is related to the cellular glutathione (GSH) system. 
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Glutathione, which is a non-protein thiol, binds its thiol to the reactive site of a drug, 
resulting in a glutathione-drug conjugate, catalyzed by glutathione-S-transferase 
(GST). The target drugs are mainly alkylating agents such as chlorambucil and 
melphalan. The conjugate is less active and more water-soluble； and excreted out of 
the cells through the transporter protein GS-X. In the tumor cells resisting to 
alkylating agents, it is often found that there is higher level of glutathione or 
increased activity of glutathione-S-transferases (Tew et al. 1994). 
III. Alteration in drug target 
Different anticancer drugs work by different mechanisms and target at different 
molecules. Drug resistance is induced when there is structural change in target 
protein, increase in the concentration of target protein or enhanced drug-induced 
damage. For topoisomerase II, it was found that there are mutations in the gene 
encoding topoisomerase II in the multidrug resistant cells. For dihydrofolate 
reductase (DHFR), which is the target of methotrexate, it was found to be increase in 
quantity in the cell lines resistant to methotrexate. As many alkylating drugs target at 
DNA, the increased activity of DNA repair system also participate in drug resistance 
f 
as cancer cells are not able to undergo programmed cell death upon drug damage 
(Stavrpvskaya et al. 1999, Lage et al. 2008). 
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IV. Alteration in drug-induced apoptosis 
Upon cytotoxic damage to tumor cells, the cells undergo apoptosis, which is the 
last step of chemotherapy. Apoptosis involves a network of proteins and pathways, 
such as p53, BCL-2 family and PTEN. p53 is a tumor suppressor which is activated 
when the cell is injured and initiates apoptosis. It is frequently found to be impaired 
in tumor, so the cells become unable to die via apoptosis. The alteration in p53 
function causes changes of tumor cells in drug sensitivity, leading to drug resistance. 
There is a large family of gene coding anti-apoptotic proteins, such as BCL-2, BCL-XL, 
and pro-apoptotic proteins, such as Bad and Bix. When there is overexpression of 
anti-apoptotic proteins which inhibits apoptosis induced by p53 or downregulation of 
pro-apoptotic protein which acts in response to p53 signal, it leads to resistance in 
tumor cells. Phosphate and tensin homolog (PTEN) is a tumor suppressor which acts 
as a inhibitor of phosphatidylinositol 3'-kinase (PI3'K) PKB/Akt signaling pathway that 
controls cell survival. The inactivation of PTEN also leads to drug insensitivity of 
tumor cells (Viktorsson et al. 2005, Hannun et al. 2011). 
I 
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1.3 Aim of study 
Many genes and proteins were found to be related to multidrug resistance in 
tumor cells. According to the previous study of our laboratory, it was found that 
there are a number of genes that are transcriptionally different in resistant cell lines 
compared to the drug sensitive cell lines. Therefore, in this study, two human uterine 
cell lines, the multidrug resistant uterine sarcoma cell line (DX5) and its parental drug 
sensitive uterine sarcoma cell line (SA), were used to elucidate the drug resistance 
mechanism of it. Moreover； two genes, Ninjurinl and Thrombospondinl, were 
chosen to investigate their role in regulating multidrug resistance. It was hoped that 
this study could explore novel multidrug resistance related gene, so as to provide a 















































































































































































































































































































































































































































































































































































































































































































































































































































































































Uterine sarcoma is a relatively uncommon group of tumors which account for 
4-9% of all uterine malignancy (Zagouri et al, 2009). It was suggested uterine 
sarcoma may be arisen from previous exposure to radiation therapy or the use of 
tamoxifen. Uterine sarcoma could be classified into four main types: 
Carcinosarcomas, Endometrial stromal sarcomas, Leiomyosarcomas, and a small 
portion of unclassifiable high-grade tumors. Despite the low incident rate； uterine 
sarcoma shows highly aggressive properties. It shows high lymph node metastases 
incidence rate at 15-20%, high propensity of local recurrence and complexicity in 
chemo-sensitivity (Papadimirious et al, 2007; Reed et al, 2008). However； its rarity 
and aggressive behaviors make treatment of uterine sarcoma a challenging topic. 
Current treatment of uterine sarcoma mainly focuses on radiotherapy and 
chemotherapy. Radiotherapy showed benefit in disease specific survival restricted to 
stage IV disease but little benefit on overall survival (Nemani et al, 2008; Smith et al, 
2008). Chemotherapy was another primary treatment for uterine sarcoma. Among 
the wide range of anti-cancer drugs, Doxorubicin is the most commonly used 
chemotherapeutic drug regarding the treatment of uterine sarcoma. It showed 
approximately 20% response rate in using doxorubicin alone. To increase the 
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effectiveness, doxorubicin is also used in combination with other anti-cancer drug； 
such as cisplatin and paditaxel. The response rate increases to 24-73% in anti-cancer 
drug combined with doxorubicin. However, the high dosage and prolong use of 
doxorubicin leads to cardioxicity and the development of Multidrug resistance (MDR) 
(Reed et al, 2008; Amant et al, 2009). 
Drug resistance, which is controlled by a complex network of pathways； makes 
the treatment of uterine sarcoma even more complicated. MDR in cancer cells is 
often found to be relating to the up-regulation of efflux pump protein of the 
ATP-binding cassette (ABC) family. Many ABC inhibitors were used in combination 
with anti-cancer drug to overcome the problem of drug resistance in chemotherapy. 
A recent research demonstrated that euphorbiasteroid could reverse 
P-glycoprotein-mediated MDR in human sarcoma cells (Choi et al, 2010). However, 
the use of inhibitors is reversible and they may cause cytotoxicity to cells. Therefore； 
it was important to clearify the mechanisms regulating the Doxorubicin-mediated 
MDR behavior of cancer cells. 
i 
As Doxorubicin (Dox) is one the major chemotherapeutic agent used in uterine 
sarcoma treatment； the pair of commercially available human uterine sarcoma 
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Dox-sensitive (SA) and Dox-resistant (DX5) cell lines were used throughout this study 
to demonstrate the underlying mechanisms regarding MDR. In this chapter, the 
difference in gene expression and drug sensitivity of these two cell lines were studied 
so as to confirm the cause of MDR establishment in DX5 cells. 
i 
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2.2 Material and Methods 
2.2.1 Materials 
2.2.1.1 Cell lines 
Human uterine sarcoma cell line MES-SA (SA) was purchased from the American 
Type Culture Collection (Baltimore, MD, U.S.A.). It was derived from a poorly 
differentiated uterine sarcoma obtained from a 56-year-old female Caucasian. 
Multiple drug resistant cell line MES-SA/DX5 was purchased from the American 
Type Culture Collection (Baltimore, MD, U.S.A.). It was derived from MES-SA by 
growing SA cell line in the presence of increasing concentrations of doxorubicin. It 
expresses high level of MDRl mRNA and P-glycoprotein. 
2.2.1.2 Cell culture medium, supplements and buffers 
I. Dulbecco's Modified Eagle's Medium (DMEM) 
DMEM culture medium was used to cultivate SA and DX5 cells. DMEM culture 
medium was prepared by dissolving GIBCO DMEM powder, which was purchased 
from Gibco Invitrogen Life Science Technologies Inc. (U.S.A.) in deionized water and 
adding 3.7 g sodium bicarbonate (NazCOs) (Sigma-Aldrich Co., U.S.A.) to each liter of 
4 
DMEM. The pH of medium was adjusted to 7.2 before filtration using a 0.22 Steritop 
filter (Millipore Express PLUS, U.S.A.). 
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II. Serum supplement 
The DMEM was supplemented with 10% GIBCO Fetal Bovine Serum (FBS), which 
was purchased from Invitrogen Life Science Technologies Inc. (U.S.A.). The serum was 
stored at -20°C as 50-ml aliquots. 
III. Antibiotic 
The DMEM was supplemented with 1% antibiotics (Penicillin and streptomycin) 
(lOOX PS), which was purchased from Invitrogen Life Science Technologies Inc. (U.S.A.) 
to constitute complete medium. The GIBCO Penicillin-Streptomycin-Glutamine (lOOX 
PS) contains 10,000 units of penicillin, 10,000 jag of Streptomycin, and 29.2 mg 
L-glutamine/ml dissolved in 0.85% saline with 10 mM citrate buffer to maintain 
penicillin potency. The PS was stored at -20°C as 5 ml aliquots. 
IV. Trvpsin-EDTA solution 
Trypsinization was performed using GIBCO 0.25% Trypsin-EDTA solution (IX), 
which was purchased from Invitrogen Life Science Technologies Inc. (U.S.A.). It 
contains 2.5 g/L trypsin of porcine origin and 0.38 g/L EDTA-tetrasodium dissolved in 
( 
Hank's balanced salt solution without calcium and magnesium. The Trypsin-EDTA 
solution was stored at-20°C as 50 ml aliquots. 
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V. Phosphate-buffered saline (PBS) 
Phosphate-buffered saline was made up by 136 mM NaCI, 2.7 mM KCI, 1.5 mM 
K H 2 P O 4 and 8 mM NaaHPCU in deionized distilled water (ddHzO). These chemicals 
were purchased from Sigma Aldrich Co. (U.S.A.). The solution was adjusted to pH 7.4 
and sterilized by autoclaving at 121°C for 20 minutes before use. The PBS was stored 
at4。C. 
VI. Doxorubicin 
Doxorubicin (Dox) was purchased from Wako Pure Chemical Industries (Japan). 
Stock solution of 1 mM and 20 mM were prepared by dissolving the Dox powder into 
sterilized deionized distillated water. The doxorubicin stocks were stored at -20°C. 
2.2.1.3 Gene expression assay reagents 
I. RNA extraction 
RNase and DNA contaminants were removed with RNase AWAY, which was 
purchased from Molecular BioProducts Inc. (U.S.A.). RNA sample was extracted from 




II. Reverse Transcription (RT) 
Reverse transcription was performed with TaqMan Reverse Transcriptase 
Reagents, which was purchased from Applied Biosystems (U.S.A.). 
III. Polymerase chain reaction (PCR) 
Polymerase chain reaction was performed with Taq PCRx DNA Polymerase 
Reagents； and primers for amplification of multidrug resistant related genes and 
GAPDH, which were purchased from Invitrogen Life Science Technologies Inc. (U.S.A.) 
IV. Agarose gel electrophoresis 
The 2% agarose gel for separation of PGR products was made by dissolving 
Ultra Pure agarose powder, which was purchased from Invitogen Life Science 
Technologies Inc. (U.S.A.), and 2 |il ehidium bromide, which was purchased from 
Pharmacia Biotech (U.S.A.) (10 mg/ml) in IX TBE buffer, which was purchased from 
Genesee Scientific Corporation (U.S.A.), containing Tris base, boric acid and EDTA). 
GeneRuler lOObp DNA ladder, which was purchased from Fermentas International 
Inc. (Canada), was used as the DNA marker. 6X sample loading buffer was prepared 
by dissolving 0.25% w/v bromophenol blue and 40% w/v sucrose in deionized 
distilled water and stored at 4。C. 
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2.2.1.4 Western blotting reagents 
I. Cell lysis buffer 
The cells were harvested and protein was extracted with Lammeli's solution 
containing 2.1 ng/ml aprotinin, 0.5 jjg/ml leupeptin, 4.9 mM MgCb； ImM 
ortho-vanadate, 1% Trinton X-100 and ImM phenylmethanesulonyl fluoride. The 
chemicals were purchased from Sigma Aldrich Co. (U.S.A.). The solution was freshly 
prepared before protein extraction and kept on ice. 
II. 2X sampling buffer 
2X sampling buffer added to protein extract before boiling was prepared by 
dissolving 1.51 g Tris Base, 20.0 g Glycerol, 10.0 ml 2-Mercaptoethanol, and 4.6 g SDS 
into deionized distilled water. The chemicals were purchased from Sigma Aldrich Co. 
(U.S.A.). The solution pH was adjusted to 6.8 before adding up volume to 100 ml. 
Bromophenol Blue was added to make solution dark enough. 
III. Bicinchoninic acid (BCA) assay reagents 
Bicinchoninic acid (BCA) assay was performed by mixing reagent A, which was 
( 
bicinchoninic acid, and reagent B, which was made by dissolving CuSCU • SHzO in 
concentration 4% w/v in deionized distilled water. The chemicals were purchased 
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from Sigma Aldrich Co. (U.S.A.). 
IV. Bovine serum albumin (BSA) standard 
Bovine serum albumin was purchased from Sigma Aldrich Co. (U.S.A.). The 
standards of 0.5-10 |ig/|il were prepared by dissolving the powder in PBS. The 
albumin powder was stored at 4°C whereas the standard solution was stored at -20 
� C , • 
V. IX sample loading buffer 
IX sample loading buffer was prepared by dissolving 0.757 g Tris Base, 10.0 g 
Glycerol, 10.0 ml 2-Mercaptoethanol, 2.3 g SDS into deionized distilled water. The 
chemicals were purchased from Sigma Aldrich Co. (U.S.A.). The solution pH was 
adjusted to 6.8 before adding up volume to 100 ml. Bromophenol Blue was added to 
make solution dark enough. 
VI. N.N.N^N^-Tetra-methvlethvlenediamine (TEMED) 
TEMED was purchased from BioRad (U.S.A.) and was stored at 4。C in 
light-exclusive container. 
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VII. Ammonium persulfate (APS) 
10% w/v working Ammonium persulfate was prepared by dissolving 0.1 g APS 
powder, which was purchased from BioRad, in 1 ml deionized distilled water and 
stored at -20°C. 
VIII. Acrvlamide/bis Solution 
30% w/v N,N'-methylene-bis-acrylamide electrophoresis purity reagent (37.5:1), 
composing of 146.1 g acrylamide and 3.9 g N,N'-methylene-bis-acrylamide in 500 ml 
ready-to-use solution, was purchased from BioRad at 4°C in light exclusive container. 
IX. 4X Lower gel buffer 
4X Lower gel buffer was prepared by dissolving 90.8 g Tris Base and 2.0 g SDS in 
deionized distilled water. The chemicals were purchased from Sigma Aldrich Co. 
(U.S.A.). The solution pH was adjusted to 8.8 before adding up volume to 500 ml. 
X. 4X Upper gel buffer 
4X Upper gel buffer was prepared by dissolving 30.0 g Tris Base and 2.0 g SDS in 
4 
deionized distilled water. The chemicals were purchased from Sigma Aldrich Co. 
(U.S.A.). The solution pH was adjusted to 6.8 before adding up volume to 500 ml. 
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XI. SDS running buffer 
lOX running buffer was prepared by dissolving 30.3 g Tris Base, 144.0 g Glycine 
and 10.0 g SDS in 1000 ml deionized distilled water. The SDS running buffer was 
diluted into IX before use. 
XII. Electroblot buffer (E-blot buffer) 
E-blot buffer was prepared by mixing 66.7 ml lOX Tris-Glycine of pH 8.3, 100 ml 
methanol and 500 ml deionized distilled water. lOX Tris-Glysine was prepared by 
dissolving 30.3 g Tris Base and 144.0 g glycine in IL deionized distilled water. 
XIII. Polvvinvlidene fluoride (PVDF) membrane 
PVDF membrane with pore size 0.45 pirn was purchased from Millipore 
Corporation (U.S.A.) and cut into size of 5.5 cm x 8.5 cm before use. 
XIV. Phosphate-buffered saline-Tween (PBST) washing buffer 
PBST was prepared by adding 1 ml Tween 20, which was purchased from USB 
Corporation (U.S.A.), into 1 L IX PBS. 
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XV. Blocking solution (5% non-fat milk solution) 
Blocking solution was prepared freshly by dissolving non-fat milk powder 
(Nestle； U.S.A.) in PBS at the concentration 5% w/v. 
XVI. Antibodies 
Primary antibodies 
Mouse monoclonal anti-Pglycoprotein was purchased from Calbiochem. Mouse 
monoclonal anti-p-actin was purchased from Sigma Aldrich Co. (U.S.A.). The primary 
antibodies were stored at -20°C. 
Secondary antibodies 
Horseradish peroxidase (HRP)-conjugated goat anti-mouse immunoglobulin G 
(IgG) was purchased from Zymed and stored at 4°C. 
XVII. Western blotting detection reagent and films 
Enhanced chemiluminescence (ECL) reagents were purchased from GE 
Healthcare (U.K.) and stored at 4°C. Medical X-ray films were purchased from Fujifilm 
I 
Corporation (Japan) and kept in dark. 
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2.2.1.5 MTT assay reagents 
I. Methvlthiazoletetrazolium (MTT) 
3-{4;5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide powder was 
purchased from USB Corporation. 1 mg/ml working solution was prepared by 
dissolving the powder in sterile PBS and stored at 4°C in light exclusive container. 
II. Dimethyl sulfoxide _ S 0 、 
DMSO was purchased from Sigma Aldrich Co. (U.S.A.) and stored in light 
exclusive container. 
2.2.1.6 Apoptosis analysis by flow cytometry reagents 
I. Annexin V-FITC 
Annexin V-FITC Apoptosis dection kit was purchased from Bender MedSystems 
(U.S.A.) and stored at -20°C. 
II. Propidium iodide solution (PI) 
2 mg/ml propidium iodide stock solution was prepared by dissolving PT powder, 
( 
which was purchased from Sigma Aldrich Co. (U.S.A.), in deionized distilled water and 
stored at 4°C. 
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III. Annexin V binding buffer 
Annexin V binding buffer was prepared by dissolving 0.48 g HEPES, 1.64 g NaCI 
and 0.147 g CaCb in deionized distilled water. The pH of the solution was adjusted to 




2.2.2.1 Cell Culture 
The cells were cultured in 100-mm culture dish with 10 ml DMEM medium or 
150 cm^ tissue culture flask with 25 ml DMEM medium in humidified incubator at 37 
°C supplying 10% CO2. Subculture was done every three or four days when about 
70-80% of the bottom area was covered with cells. Cells were harvested in different 
growth phases for different assays. 
For subculture； the culture medium was removed and the cells were washed 
with pre-warmed PBS. The cells were then trypsinized by incubating the cells with 3 
ml trypsin-EDTA solution at 37°C for 5 minutes. DMEM medium was used to stop 
the trypsinization afterwards and then the cell suspension was centrifuged at 1000 x 
g for 5 minutes. The supernatant was discarded and the cell pallet was re-suspended 
with DMEM medium. After cell number counting, suitable amount of cells were 
seeded into a new culture dish or flask with complete medium for culture or different 
assays. 
I 
For long time storage, 10% DMSO was added to the cell suspension with 
complete medium and kept in liquid nitrogen. 
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2.2.2.2 MTT assay 
The viability of cells was measured by MTT assay. 1 x 10^  cells were seeded onto 
each well on a 96-well culture plate (IWAKI, Japan) and incubated for 24 hours in a 
humidified incubator with 5% CO2 supplied at 37°C. Appropriate concentrations of 
Dox were added to the cells and the cells were allowed for incubation at 37°C for 
further 48 hours. 
After 2 days incubation with the anticancer drugs； the cells were treated with 50 
\x\ of MTT solution (1 mg/ml in PBS) at 37°C for 2 hours and lysed in 150 …o f 
dimethyl sulfoxide (DMSO) at room temperature for 45 minutes. The absorbance of 
each well was measured at 570 nm in mi crop I ate reader. The absorbance is directly 
proportional to the survival of cells. The percentage of cell viability was calculated as 
follows: 
% viability = [OD540 of test sample/OD54o of control] x 100% 
The cell survival was analyzed by Student's t test. 
( 
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2.2.2.3 Gene expression essay (RT-PCR) 
I. Total RNA extraction 
3x10^ cells were cultivated on a 35-mm culture dish for 48 hours and harvested 
by trypsinization. Total RNA was extracted with NucleoSpin® RNA II total RNA 
Isolation Kit. 350 |il RAl and 3.5^ 1 p-mercaptoethanol were added to the cell pellet 
and vortexed vigorously to lyse the cells. The mixture was then transferred to a 
NucleoSpin Filter in a collection tube and centrifuged for 1 minute at 11,000 x g to 
reduce viscosity and clear the lysate. The Filter was discarded and the filtrate was 
added with 350 |il 70% ethanol to homogenize the lysate. The lysate mixture was 
transferred to a NucleoSpin RNA II Column in a collection tube and centrifuged for 30 
seconds at 11,000 x g to bind RNA. 350 |il MDB was added to the column and 
centrifuged for 1 minute at 11,000 x g to desalt silica membrane. DNase rection 
mixture was prepared by mixing 10 |il reconstituted rDNase and reaction buffer for 
rDNase per isolation. 95 |il DNase reaction mixture was applied to the center of the 
membrane of the column and incubated at room temperature for 15 minutes. The 
column was washed by adding 200 |il buffer RA2 and centrifuging for 30 seconds at 
11/000 X g. Then the column was washed by adding 600 |il RA3 and centrifuging for 
( 
30 seconds at 11,000 x g. After that； the column was washed by applying 250 |il RA3 
and centrifuging for 2 minutes at 11,000 x g for complete dryness. Finally, the column 
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was transferred to a 1.5 ml tube and 60 |il RNase-free H2O was added and 
centrifuged for 1 minute at 11,000 x g to elute the RNA. RNA concentration was 
measured by spectrophotometer (Eppendorf, U.S.A.) measuring the absorbance at 
260 nm. The A260/A280 ratio was ranged between 1.8 and 2.4 for quality control. The 
RNA elute was stored at -80。C or subjected to RT-PCR. 
II. Reverse-transcriptase Polvmerase-Chain Reaction (RT-PCR) 
RT-PCR was carried out for smei-quantitative analysis of the mRNA levels of 
different genes. With equal number of cycles； the band intensity increased 
proportionally to the amount of mRNA present. 
1000 ng of total RNA was reversely transcribed to complementary DNA (cDNA) 
and PGR was carried out for amplification of target genes. 
The reverse-transcription of mRNA into cDNA was performed by TaqMan 
Reverse Transcription Reagents (Applied Biosystems； U.S.A.). Each reaction was 
prepared with the following reagents on ice. 
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Volume (|il) 
lOX Reaction Buffer 5 
25 mM MgClz 11 
10 mM dNTP 10 
Random Hexamer (50 ng/nl) 1.25 
.. 50 ^M Oligo d(T)i6 
RNase Inihibitor (20U/nl) 1 
Reverse Transcriptase (50U/nl) ‘ 0.5 
dHaO Total of 20 
RNA sample 
cDNA synthesis was performed using the following program of the 
thermo-cycler (GeneAmp PGR System 9700, Applied Biosystems, U.S.A.): 
25°C for 10 minutes; 
37°C for 60 minutes; 
95°C for 5 minutes 
The cDNA synthesized was stored at -20°C before subjecting to the amplification 
of targeted genes by PGR. 
Taq PCRx DNA Polymerase Reagents (Invitrogen, U.S.A.) were used for PGR. Each 
reaction was prepared with the following reagents on ice. 
Volume (…） 
IPX PCR Buffer Minus Mg++ —~2 
AOmM dNTP 0.4 
50mM MgCl2 0.6 : 
lOuM Primer mix 1 
cDNA template 2 
5U/ul Taq DNA Polymerase 0.1 
Autoclaved ddH20 13.9 
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PGR was performed using the following thermal cycling program: 
94°C for 5 minutes; 
94°C for 50 seconds;、 
58°C for 50 seconds; > 30 cycles 
72°C for 50 seconds;〉 
72°C for 10 minutes 
10 multi-drug resistant related genes and GAPDH were selected for PGR. The 
primers of genes were shown in the following table. 
Primer set Sense primer, Antisense primer, 
MRPl CAGCATGAGCTACTTGCCG TTCCTCCTCGTCCATCACTGT 
MRP2 CCACTTGTTTGAGCAAACTGT CCAGCTCTATGGCTGCTAGAA 
MRP3 ATTTGGAATCTAACATCGTGGCT GCCGGTAGCGCACAGAATA 
MRP4 GGACGCGAACATCTGCTCA CTTCTGGCAGCACTGAATACAT 
MRP5 AGAACTCGACCGTTGGAATGC TCATCCAGGATTCTGAGCTGAG 
MRP6 AGATGGTGCTTGGATTCGCC GCCACACAGTAGGATGAATGAG 
MRP7 CGACTCCGGGTCATCAAATAC TCTACCACAATCTGGGCTGTA 
MRP8 GTGAATCGTGGCATCGACATA GGGCCATCTTGGAGAGTATAGG 
BCRP CCCGCGACAGTTTCCAATGA GGCGTTGAGACCAGGTTTCA 
MDRl GGAACTCAGCTCTCTGGTGG CTTCTCTGGCTTTGTCCAGG 
GAPDH CAGCCGAGCCACATCG TGAGGCTGTTGTCATACTTCTC 
The PCR products were resolved by gel electrophoresis in which 2% agarose gel 
was pre-stained with ethidium bromide and visualized by a ultra-violet light cabinet 
I 
(Alpha Innotech Corporation, U.S.A.). 
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2.2.2.4 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of 
protein lysate and Western blotting 
I. Protein extraction 
3 X 10® SA cells and 5 x 10® DX5 cells were seeded on a 60 mm culture dish 
(IWAKI, Japan) for 48 hours to allow adhesion and were harvested using Lammeli's 
solution. The lysates were centrifuged at 15,000 x g for 7 minutes at 4°C. The 
supernatants were transferred to a new microfuge-tube, added with 2X SDS sampling 
buffer and boiled for 10 minutes before storage at -20°C. 
II. Determination of protein concentration 
The protein concentration of extracted sample was determined by bicinchoninic 
(BCA) assay. Reacting mixture was prepared by mixing reagent A (BCA) and reagent B 
(4% w/v CUSO4 • 5H2O) in the ratio of 49:1. 200 |il reaction mixture and 0.5 |il protein 
sample or BSA standards were added to each well on a 96 well plate in triplicate. The 
mixture were incubated for 30 minutes at 37°C. The absorbance at 540 nm was 
measured by a microplate reader (Bio-rad, U.S.A.). Protein concentration of the 
samples was calculated according to the BSA standard curve. 
I 
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III. SAS-Polvacrvlamide gel electrophoresis (SDS-PAGE) 
30 ng of protein from each sample was mixed with IX SDS loading buffer 
making up to 20 loading mixture. The mixture was loaded onto a 8% SDS-PAGE for 
P-glycoprotein (Pgp) and Thrombospondinl (THBSl)； 12% SDS-PAGE for P-actin and 
15% for Ninjurinl (Ninjl), then subjuected to electrophoresis at 200 V for 50-60 
minutes for protein separation by BIORAD Mini-ROTEAN III Cell system. 
The upper stacking gel and lower separating gel were prepared as shown below 
4.5% upper gel 8% lower gel 12% lower gel 15% lower gel 
Acrylamide 1.2 ml 4.27 ml 6.4 ml 8 ml 
solution (30%) 
4X Upper gel 2.0 ml -- -- -
buffer 
4X Lower gel -- 4 ml 4 ml 4 ml 
buffer 
Deionized 4.8 ml 7.63 ml 5.5 ml 3.9 ml 
water 
10% APS 18.6 nl 18.6 … 18.6 |il 
TEMED 10.6 lil 80 |il 80 pi 80 [i\ 
IV. Semi-dry transfer of protein to PVDF membrane 
The Polyvinylidene fluoride (PVDF) membranes were pre-wetted in 100% 
methanol and equilibrated in E-blot buffer. The protein on the SDS-PAGE was 
transferred to the membrane by Trans-Blot SD Semi-Dry Transfer Cell system with'a 
constant current of 0.15 A for 30 minutes. 
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V. Enhanced chemiluminescence (ECL) detection 
The membrane was incubated with 5% non-fat dry milk in PBS at 4°C overnight 
for blockage. The membrane was washed with PBST for 2 times, 10 minutes each and 
then probed with primary antibodies for 2 hours. After that, the membrane was 
washed with PBST for 2 times, 10 minutes each before probing with respective 
horse-radish peroxidase conjugated secondary antibodies for further 2 hours. The 
primary antibodies used in this study were anti-Pglycoprotein (CalBiochem, U.S.A.) 
and anti-P-actin (Sigma Aldrich Co.； U.S.A.). 
After secondary probing, the membrane was washed with PBST for 2 times, 15 
minutes each. The chemiluminscent signals of the bands were detected by the ECL 
Western blotting detection reagent. Individual protein band was scanned and 
analyzed by software of Kodak Digital Science ID Image (version 3.0). 
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2.2.2.5 Quantification of doxorubicin uptake by flow cytometry 
3 X IQS cells were seeded onto a 6-well microplate (IWAKI, Japan) and incubated 
for 48 hours in a humidified incubator with 5% CO2 supplied at 37°C. The medium 
was changed and 10 uM doxorubicin was added to the cells and incubated for 4 
hours at 37°C. The cells were trypsinized and washed with PBS twice. The samples 
were then analyzed by FACSCanto Flow Cytometer (BD Biosciences, U.S.A.). The 




2.2.2.6 Apoptosis analysis by flow cytometry 
Annexin V-FITC Apoptosis dection kit (Bender MedSystems, U.S.A.) was used for 
Apoptosis Analysis of cells. 3x 10^  cells were seeded onto a 6-well microplate (IWAKI, 
Japan) and incubated for 24 hours in a humidified incubator with 5% CO2 supplied at 
37°C for adhesion before addition of doxorubicin (Dox). After addition of Dox (0 jiM； 
2.5 nM and 1 0 _ , the cells were incubated for further 48 hours at 37。C. The cells 
were harvested and washed twice with PBS. The cells were then resuspended in IX 
Annexin V binding buffer at a density of 2-5 x 10^  cells/ml. 5 pil Annexin V/FITC and 
0.5 \x\ propidium iodide (PI) solution were added in every 0.5 ml Annexin V binding 
buffer. The mixture and cells were incubated at room temperature for 15 minutes in 
dark. The samples were analyzed by FACSCanto Flow Cytometer (BD Biosciences, 
U.S.A.) and the signals were detected by PE-A and FITC channels. The data was 
collected and analyzed by software WinMDI v2.9. 
The Annexin V-GFP binds to the phosphatidylserines (PS) which extend along 
the plasma membrance and are translocated to the external cellular environment 
during early apoptosis. As for propidium iodide (PI), it binds to the DNA when the cell 
i 
membrane is lysed. The high intensity of green fluorescence signal contributed by 
Annexin V-GFP indicates early apoptosis. Whereas high intensity in both green 
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fluorescence signal contributed by Annexin V-GFP and red fluorescence signal 











2.3.1 Cytotoxicity of doxorubicin on SA and DX5 cells 
DX5 is the drug resistant uterine cell line derived from SA. To assess the 
difference in drug resistance between SA and DX5 cells； MTT assay was performed to 
determine the dose-response relationship between Dox and the cells. The IC50 of the 
parental SA cell was 0.15 |iM after Dox incubation for 48 hours, while that of DX5 cell 
was 10 |iM. The resistance index was about 66.7, indicating that the DX5 cells were 
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Figure 2.1 Cytotoxicity of Doxorubicin (Dox) on SA and DX5 cells 
Cell survival was investigated by MTT assay 48 hours after same concentration of 
Doxorubicin treatment on SA and DX5 cells. The DX5 cells were more resistant than 
the SA cells. Each point was expressed as the mean of 3 independent experiments, 
each consisted of 6 replicates 士 SD. ***P<0.001, Student's t test. 
i 
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Figure 2.2 Cytotoxicity of Doxorubicin (Dox) on SA and DX5 cells 
Cell survival was investigated by MTT assay 48 hours after different concentration 
Doxorubicin treatment on SA and DX5 cells. The IC50 of SA cells were found to be 0.15 
|iM. The IC50 of DX5 cell sere found to be 10 |iM. Each point was expressed as the 
mean of 3 independent experiments, each consisted of 6 replicates 土 SD. 
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2.3.2 mRNA expression of multidrug resistance related genes in SA and DX5 cells 
Multidrug resistance was mainly found to be related to the upregulation of 
genes encoding efflux pump in the ATP-binding cassette proteins family. 
Semi-quantitative RT-PCR was performed to determine the level of MRPl, MRP2, 
MRP3, MRP4, MRP5, MRP6, MRP7, MRP8, BCRP and MDRl in SA and DX5 cells to 
find out the gene contributing to higher drug resistance level in DX5 cells compared 
to SA cells. 
According to the RT-PCR result, there was a significant higher MDRl expression 
in DX5 cells than SA cells. However, there was no obvious difference in expression of 
other multidrug resistance related genes between SA and DX5 cells. With the 
software Image J, the RT-PCR result was statistically analyzed by normalizing to a 
housekeeping gene, GAPDH. It was found that the MDRl expression in DX5 cells was 
about 7 fold higher than in SA cells. 
• r 
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Figure 2.3 mRNA expression of multidrug resistance related genes in SA and DX5 
cells 
mRNA was isolated and reverse transcribed into cDNA. cDNA was amplified by PGR. 
The amplified DNA was separated by 2% agarose gel pre-stained with ethidium 
bromide and the image was captured under UV light illumination. The DX5 cells 
showed significant overexpression in MDRl gene, but no significant difference in 
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Figure 2.4 Statistical analysis of mRNA expression of multidrug resistance related 
genes in SA and DX5 cells 
The captured image of PCR result was analysized with software Image J. The mRNA 
expression of multidrug resistance genes were normalized to a housekeeping gene； 
GAPDH. The expression of genes in DX5 cells were calculated relative to the 
expression in SA cells. It was found that the DX5 cells showed about 7.31 土 4.34 fold 
overexprssion of MDRl compared to SA cells. Each bar was expressed as the mean of 
6 independent experiments 土 SD. *P<0.05, Student's t test. 
r 
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2.3.3 P-glycoprotein expression in SA and DX5 cells 
To investigate the overexpression of MDRl in protein level； Western blotting 
was carried out to show the P-glycoprotein expression in SA and DX5 cells. The band 
intensity developed by the enhanced chemiluminescence detection kit is directly 
proportional to the amount of protein present in the sample and the house-keeping 
protein P-actin was used as the internal control for the assay. As shown in Figure 3.5； 
there was little expression of P-glycoprotein in SA cells, whereas there was 
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Figure 2.5 The P-glycoprotein expression in SA and DX5 cells 
The total protein was extracted from SA and DX5 cells and Western blotting was 
performed. The presence of specific protein was detected by ECL reagents and X-ray 
film. The house-keeping protein p-actin was used as the internal control for the assay. 
There was significant overexpression of P-glycoprotein in DX5 cells but not SA cells. 
Figure shown was the representative results of 6 independent trials. 
i 
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2.3.4 Doxorubicin (Dox) uptake by SA and DX5 cells 
P-glycoprotein is an efflux pump that can extrude Dox from cells. The amount of 
internalized Dox of cells reflects the activity of P-glycoprotein in cells. The cellular 
Dox uptake by SA and DX5 cells were determined by flow cytometry. Dox possesses 
fluorescent property, so the extent of its internalization was detected directly by the 
fluorescence intensity through the PE-A channel. 
After treating the SA and DX5 cells with 10 [xW\ Dox for 4 hours； 99.2% of SA cells 
showed internalized Dox； while 3.18% DX5 cells show internalized Dox. This indicated 











































































Figure 2.6 Doxorubicin (Dox) uptake by SA and DX5 cells 
SA and DX5 cells were treated with 10 |iM Dox for 4 hours. Cells were harvested and 
washed. The intracellular fluorescent intensity was measured by flow cytometry. In 
graph (A)； red and black peak corresponded to SA and DX5 cells respectively. M l 
showed the population of cells with internalized Dox, with SA cells as the fully 
internalized control. Graph (B) showed the mean of population of cells with 
internalized Dox. SA cells showed 99.2% 土 0.30 Dox internalized; while DX5 cells 
showed 3.18% ± 0.65 Dox internalized. Data was expressed as the mean of 6 
independent experiments 土 SD. ***P<0.001； Student's t test. 
I 
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2.3.5 Doxorubicin induced Apoptosis in SA and DX5 cells 
To assess the Dox-induced apoptosis of SA and DX5 cells, the cells were treated 
with 0 |iM, 0.005 ^M and 0.02 |iM Dox for 48 hours and then stained with Propidium 
Iodide (PI) and Annexin V-GFP. The Annexin V-GFP binds to the phosphatidylserines 
(PS) which extend along the plasma membrance and are translocated to the external 
cellular environment during early apoptosis. As for propidium iodide (PI), it binds to 
the DNA when the cell membrane is lysed. The high intensity of green fluorescence 
signal contributed by Annexin V-GFP indicates early apoptosis. Whereas high 
intensity in both green fluorescence signal contributed by Annexin V-GFP and red 
fluorescence signal contributed by Propidium Iodide (PI) indicates late apoptosis or 
necrosis. 
It was shown that the proportion of apoptosis and late-apoptosis of SA cell after 
treatment increased dose-dependently; While DX5 cell did not shown significant 
difference in proportion of apoptosis and late-apoptosis throughout these three 
concentrations of Doxorubicin treatment. 
I 
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(A) SA cells treated with 0 [xW\ Dox 
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(C) SA cells treated with 0.02 |iM Dox 
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(D) DX5 cells treated with 0 pM Dox 
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(E) DX5 cells treated with 0.005 _ Dox 
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(G) Apoptotic proportion of SA cell treated with 0 \xW\, 0.005 ^M and 0.02|iM Dox 
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Figure 2.7 Doxorubicin induced Apoptosis in SA and DX5 cells 
SA cells were treated with 0 |iM, 0.005 |iM and 0.02 |aM Dox and the results were 
shown in graph (A) to (C). DX5 cells were treated with 0 |iM, 0.005 |iM and 0.02 \xW\ 
Dox and the results were shown in graph (D) to (F). The cells were co-stained with 
Propidium Iodide (PI) and Annexin V-GFP and the fluorescent intensity was measured 
by flow cytometry. Graph (A) to (F) showed representative data of 3 independent 
experiments. The statistical result was analysized with WinMDI (v.2.9). The result was 
summarized as in graph (G) and (H) for SA and DX5 cells respectively. Each bar was 





Chemotherapy has been the major treatment of malignancy, but the 
development of multidrug resistance (MDR) in malignant cell causes the failure in 
successful treatment. Doxorubicin (Dox) is the most frequently used cytotoxic drug in 
cancerous treatment (Park et al. 2006). However, a lot of studies have revealed that 
the exposure of cancerous cells to doxorubicin leads to the development of 
multidrug resistance in many different kinds of cancer, such as human hepatocellular 
carcinoma, human bladder cancer, leukemia, etc. The development of multidrug 
resistance could be due to a wide range of alternations in cells as stated in chapter 1. 
Among them, the most common one was the up-regulation of transmembrane efflux 
pumps. 
In this study； a pair of human uterine sarcoma cells SA and DX5 was used. DX5 
cells possess drug resistance； which was developed from the parental drug sensitive 
uterine sarcoma cells SA through stepwise treatment of doxorubicin, referring to 
information provided by the supplier, ATCC, U.S.A.. To investigate the difference in 
resistant level of SA and DX5 cells to Dox； MTT was performed. As seen in Figure 2.1, 
< 
SA cells showed a decreased in cell viability in a dose-dependent manner with 
f 
increasing concentration of Dox from 0 |iM to 0.1 \xW\; while DX5 cells showed 
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resistant to Dox treatment. By comparing the IC50 of 0.15 |iM in SA cells and the IC50 
of 10 \xW\ in DX5 cells； it was found that the DX5 cells was 66.7 fold more resistant 
than SA cells towards Dox treatment. 
Previous study has found that the development of MDR was contributed by the 
over-expression of ATP binding cassette (ABC) family of transmembrane transporters. 
To investigate the alternation in gene expression DX5 cells leading to higher drug 
resistance, RT-PCR was performed with 10 selected multidrug resistant related genes 
in SA and DX5 cells. As shown in figure 2.2, DX5 cells only showed an obvious 
difference in multidrug resistance gene 1 (MDRl), but not the multidrug 
resistance-associated proteins (MRPs) and breast cancer resistance proteins. By 
semi-quantitative method, it was found that the expression of MDRl mRNA in DX5 
cells were about 7 fold higher than in SA cells. Western blotting of the P-glycoprotein 
which is encoded from MDRl also showed consistent result as that of RT-PCR. DX5 
cells showed high expression of P-glycoprotein； while SA cells only showed 
non-detectable amount. It was confirmed that the acquisition of Dox resistant in DX5 
cells was due to up-regulation of multidrug resistant genel in transcription level； and 
I 
over-expression of P-glycoprotein in translation level. This showed consistency with 
previous study in Dox-derived MDR variant cell lines including human bladder cancer 
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cell ADMR (Guo et al. 1997), human hepatocarcinoma R-HepG2 (Tang et al. 2009) 
‘： r . ‘‘ '"?. 
and human mammary adenocarcinoma MGF-7R (Labbozzetta et al. 2009) that MDR 
was mediated by the over-expression of P-glycoprotein in these cell lines. 
. (S ； 
As a unidirectional efflux pump, P-glycoprotein protects the cells from extruding 
a wide range of hydrophobic molecules including Dox. After confirming the 
up-regulation of P-glycoprotein in DX5 cells； Dox uptake assay was performed by flow 
cytometry to investigate the activity of P-glycoprotein. After exposing 4 hours to 10 
|iM doxorubicin； DX5 cells showed a great reduction in Dox internalization of 3.18%, 
compared to 99.2% of parental SA cells showing Dox internalization. The reduction in 
intracellular drug accumulation in DX5 cells resulted in higher tolerance to Dox, 
which was attributed by the higher activity of P-glycoprotein in DX5 cells. 
Dox eradicates cancer cells by activating cell death machinery (Viktorsson et al. 
2005). Upon damage by cytotoxic drugs； malignant cells undergo programmed cell 
death, which is controlled by a complicated network of pathways. Cancer cells may 
attain resistance through alternation in genes controlling these pathways. Those cells 
f 
could not undergo apoptosis upon damage and keep on growing unlimitedly. The 
r 
apoptosis of cells could be measured by Annexin V-PI binding assay. As shown in 
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figure 1.1, both SA and DX5 cells showed apoptosis and necrosis. SA cells showed 
gradual increase in number of cells which undergo apoptosis and necrosis in 
response to the increased Dox concentration treatment. However, the percentage of 
apoptosis and necrosis in DX5 cells did not increase with the increase in Dox 
concentration. This result consist with the previous assays' result that the DX5 cells 
were more resistant to Dox treatment. The Annexin V-PI binding assay showed that 
DX5 cells were able to undergo apoptosis and necrosis. This further confirmed that 
the DX5 cells' resistance to Dox was due to the higher expression and activity of 
P-glycoprotein. 
A study in K562 leukemic cells discovered that Dox was able to induce the 
expression of multidrug resistance gene MDRl through the activation of FOXOSa. 
Under cytotoxic pressure induced by anti-cancer drug； FOXOSa activity was induced 
which in turns up-regulated MDRl expression at protein； mRNA and gene promoter 
level. This novel mechanism further supported our finding that the MDR in human 
uterine sarcoma cell line DX5 was due to upregulation of MDRl. 
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2.5 Conclusion 
In summary； DX5 cells were derived from SA cells by stepwise increased 
concentration of Dox treatment and developed multidrug resistance. Among the 10 
multidrug resistance related genes, it was found that the up-regulation of MDRl was 
the cause of drug sensitivity difference between SA and DX5 cells. DX5 cells showed 
higher Dox tolerance because of the higher expression and activity of the 
P-glycoprotein, hence minimizing the intracellular accumulation of drug, regardless 









Multidrug resistance (MDR) has long been a major obstacle in effective 
chemotherapy. A lot of research was carried out to reveal the underlying 
mechanisms. As demonstrated in chapter 3； many studies have found that the lower 
drug sensitivity of the resistant derivative human uterine sarcoma cell line, DX5 was 
due to the up-regulation and higher activity of P-glycoprotein. However, the 
mechanism leading to the up-regulation and higher activity of P-glycoprotein was not 
fully understood. Therefore； many large scale microarrays were done to study the 
gene expression difference between drug sensitive cell line and its multidrug 
resistant counterparts in order to gain better understanding in the mechanism of 
drug resistance development (Villeneuve et al； 2006; Zhao et al； 2007). According to 
a previous study of our group on human hepatocellular carcinoma cell line, HepG2, 
and its doxorubicin-resistant counterpart cell line； R-HepG2, which was developed by 
stepwised increased concentrations of Dox treatment on HepG2 cells , a number of 
genes were found transcriptionally different in the resistant cell line (Wang et al, 
2009). Among them； Ninjurinl was found to have significant lower transcription level 
in doxorubicin-resistant human hepatocellular carcinoma cell (RHepG2) than in the 
‘ i 
parental sensitive cell line (HepG2). This provoked our interest in examining Ninjurinl 
transcription in DX5 cells and further study was carried out and the results are 
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reported beneath. 
Ninjurinl (Nerve injury induced protein 1) is a two-pass cell surface protein. It 
consists of two hydrophobic transmembrance domains and an extracellular 
N-terminal domain which was responsible for adhesion. The adhesion motif of 
Ninjurinl enables cell-cell adhesion and communication (Araki et al, 1996). Ninjurinl 
was a novel protein that the function of it was incompletely understood. Research 
has been focusing on its role in central nervous system (CNS) and found that its 
adhesion ability enables neuronal regeneration in Schwann cells and dorsal root 
(Araki et al, 1997). Recent research revealed that it also plays a role in developmental 
processes and inflammatory response (Lee et al, 2009). Since tissue remodeling and 
inflammatory responses involve cell apoptosis and cell-cell interaction which is also 
important in cancer progression and MDR development, Ninjurinl was suspected to 
be involved in MDR of cancer cells. 
To further investigate the relationship between Ninjurinl expression and drug 
sensitivity of cancer cells, the pair of doxorubicin-resistant and doxorubicin-sensitive 
( 
human uterine sarcoma cell lines (SA and DX5) was used. Firstly, the Ninjurinl 
/ 
expression in these two cell lines was compared. Afterwards, Ninjurinl was 
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over-expressed in doxorubicin-resistant human uterine sarcoma cell (DX5) by 
transient transfection to examine whether this over-expression may cause drug 
sensitivity different in the DX5 cell. 
4 
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3.2 Materials and Methods 
3.2.1 Materials 
3.2.1.1 Cell lines 
Human uterine sarcoma cell line MES-SA (SA) and Multiple drug resistant cell 
line MES-SA/DX5 were used. The purchase information can be referred to Chapter 2. 
3.2.1.2 Cell culture medium, supplements and buffers 
Fetal bovine serum (FBS) and antibiotics (Penicillin and streptomycin) were 
added to Dulbecco's Modified Eagle's Medium (DMEM) to constitute complete 
medium. Trypsin-EDTA and phosphate-buffered saline (PBS) were used in the 
subculture of cell lines. The purchase information and ingredients can be referred to 
Chapter 2. 
3.2.1.3 Gene expression assay reagents 
I. RNA extraction 
RNase and DNA contaminants were removed with RNase AWAY； which was 
purchased from Molecular BioProducs (U.S.A.). RNA sample was extracted from cells 
I 




II. Reverse Transcription (RT) 
Reverse transcription was performed with TaqMan Reverse Transcriptase 
Reagents； which was purchased from Applied Biosystems (U.S.A.). 
III. Polymerase chain reaction (PCR) 
Polymerase chain reaction was performed with Taq PCRx DNA Polymerase 
Reagents； and primers for amplification of Ninjl and GAPDH, which vyere purchased 
from Invitrogen Life Science Technologies Inc. (U.S.A.). 
IV. Agarose gel electrophoresis 
The 2% agarose gel for separation of PCR products was made by dissolving 
Ultra Pure agarose powder； which was purchased from Invitogen Life Science 
Technologies Inc. (U.S.A.), and 2 \x\ ehidium bromide, which was purchased from 
Pharmacia Biotech (U.S.A.) (10 mg/ml) in IX TBE buffer； which was purchased from 
Genesee Scientific Corporation (U.S.A.)； containing Tris base； boric acid and EDTA). 
GeneRuler lOObp DNA ladder, which was purchased from Fermentas International 
Inc. (U.S.A.), was used as the DNA marker. 6X sample loading buffer was prepared by 
I 
dissolving 0.25% w/v bromophenol blue and 40% w/v sucrose in deionized distilled 
water and stored at 4°C. 
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3.2.1.4 Western blotting reagents 
I. Cell Ivsis buffer 
The cells were harvested and protein was extracted with Lammeli's solution, 
which was freshly prepared before protein extraction and kept on ice. The 
ingredients and purchase information can be referred to Chapter 2. 
II. Bicinchoninic acid (BCA) assay reagents and Bovine serum albumin standard 
Bicinchoninic acid (BCA) assay was performed by mixing reagent A, which was 
bicinchoninic acid； and reagent B, which was made by dissolving CuSCU • SHzO in 
concentration 4% w/v in deionized distilled water. The standards of 0.5-10 [xg/\x\ 
were prepared by dissolving the albumin powder in PBS. The chemicals were 
purchased from Sigma Aldrich Co. (U.S.A.). 
III. 2X sampling buffer and IX loading buffer 
2X sampling buffer and IX loading buffer were added to protein extract before 
western blotting. The preparation ingredients and purchasing information can be 
referred to Chapter 2. 
( 
IV. Gel setting reagents 
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TEMED, Ammonium persulfate (APS)； Acrylamide/bis Solution； 4X Lower gel 
buffer and 4X Upper gel buffer were used for gel setting. The ingredients and 
purchasing information can be referred to Chapter 2. 
V. SDS running buffer 
lOX running buffer was prepared by dissolving 30.3 g Tris Base, 144.0 g Glycine 
and 10.0 g SDS in 1000 ml deionized distilled water. The SDS running buffer was 
diluted into IX before use. 
VI. Electroblot buffer (E-blot buffer) 
E-blot buffer was prepared by mixing 66.7 ml lOX Tris-Glycine of pH 8.3, 100 ml 
methanol and 500 ml deionized distilled water. lOX Tris-Glysine was prepared by 
dissolving 30.3 g Tris Base and 144.0 g glycine in IL deionized distilled water. 
VII. Polyvinylidene fluoride (PVDF) membrane 
PVDF membrane with pore size 0.45 |im was purchased from Millipore 
Corporation (U.S.A.)and cut into size of 5.5 cm x 8.5 cm before use. 
VIII. Phosphate-buffered saline-Tween (PBST) washing buffer 
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PBST was prepared by adding 1 ml Tween 20； which was purchased from USB 
Corporation (U.S.A.)； into 1 L IX PBS. 
IX. Blocking solution (5% non-fat milk solution) 
Blocking solution was prepared freshly by dissolving non-fat milk powder 
(Nestle； U.S.A.) in PBS at the concentration 5% w/v. 
X. Antibodies 
Primary antibodies 
Mouse monoclonal anti-p-actin was purchased from Sigma Aldrich Co. {U.S.A.). 
Mouse monoclonal anti- Ninjurinl was purchased from BD Bioscience (U.S.A.). The 
primary antibodies were stored at -20°C • 
Secondary antibodies , 
Horseradish peroxidase (HRP)-conjugated goat anti-mouse immunoglobulin G 
(IgG) was purchased from Zymed (U.S.A.) and stored at 4°C. 
XII. Western blotting detection reagent and films 
I 
Enhanced chemiluminescence (ECL) reagents were purchased from GE 
Healthcare (U.K.) and stored at 4°C. Medical X-ray films were purchased from Fujifilm 
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Corporation (Japan) and kept in dark. 
3.2.1.5 Plasmid DNA extraction 
I. Competent Cells 
Competent JM109 cells were prepared following Cohen's Calcium Chloride 
method. Cells were allowed to grow for 16 hours at 37°C. A single colony was picked 
and transferred into 100 ml of LB broth. The culture was incubated, for 3 hours at 
37°C in a rotary shaker at 300 cycles per minute. The cells were collected and 
centrifuged at at 3,000 x g for 10 minutes at 4°C. The medium was discarded and the 
pellet was resuspended in 10 ml sterile 0.1 M CaClz. The suspension was stored on 
ice for 30 minutes and centrifuged at 3,000 x g for 10 minutes at 4°C. The 
supernatant was discarded and the pellet was resuspended in 2 ml strerile 0.1 M 
CaClz for each 50 ml original culture. The competent cells were stored at -80°C in , 
aliquots. 
II. Bacterial culture medium 
LB Broth and LB agar, which were purchased from USB； were used for bacterial 
• < 
culture. The medium was supplemented with 100 ng/ml ampicillin. The ampicillin 
powder was purchased from Sigma Aldrich Co. (U.S.A.)； it was diluted by deionized 
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water into 100 mg/ml and stored at -20°C. 
III. Plasmid DNA extraction 
cDNA Clones: pCMV6-AV-GFP-THBSl, pCMV6-AV-GFP-Ninjl and pCMV6-XL5 
clones were purchased from OriGene Technologies (U.S.A.). Plasmid DNA was 
extracted from bacterial cells with NucleoBond Xtra Midi kit, which was purchased 
from MACHEREY-NAGEL (Germany). 
3.2.1.6 Transient transfection 
Transfecting agent 
DNA-Lipofecatmine 2000 reagent was purchased from Invitrogen (U.S.A.) and 
stored at 4°C. 
f 
3.2.1.7 MTT assay reagents 
I. Methvlthiazoletetrazolium (MTT) 
3-(4,5-Dimethyl-2-thiazolyl)-2;5-diphenyl-2H-tetrazolium bromide powder was 
purchased from USB Corporation (U.S.A.). 1 mg/ml working solution was prepared by 
I 
dissolving the powder in sterile PBS and stored at 4°C in light exclusive container. 
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II. Dimethyl sulfoxide (DMSO) 






3.2.2.1 Cell Culture 
The cells were culture in 100-mm culture dish with 10 ml DMEM medium or 150 
cm^ tissue culture flask with 25 ml DMEM medium in humidified incubator at 37°C 
supplying 10% CO2. Subculture was done every three or four days when about 
70-80% of the bottom area was covered with cells. Cells were harvested in different 
growth phases for different assays. 
For subculture, the culture medium was removed and the cells were washed 
with pre-warmed PBS. The cells were then trypsinized by incubating the cells with 3 
ml trypsin-EDTA solution at 37°C for 5 minutes. DMEM medium was used to stop 
the trypsinization afterwards and then the cell suspension was centrifuged at 1000 x 
g for 5 minutes. The supernatant was discarded and the cell pallet was re-suspended , 
with DMEM medium. After cell number counting, suitable amount of cells were 
seeded into a new culture dish or flask with complete medium for culture or different 
assays, 
I 
For long time storage； 10% DMSO was added to the cell suspension with 
complete medium and kept in liquid nitrogen. 
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3.2.2.2 Gene expression essay (RT-PCR) 
i. Total RNA extraction 
3x10^ cells were cultivated on a 35 mm culture dish for 48 hours and harvested 
by trypsinization. Total RNA was extracted with NucleoSpin® RNA II total RNA 
Isolation Kit. Details of procedures can be referred to Chapter 2. 
As for the cells carrying out transfection； 3x105 cells were cultivated on a 35 
mm culture dish for 24 hours and subjected for transfection. The cells were allowed 
to grow for further 48 hours before harvest. 
II. Reverse-transcriptase Polvmerase-Chain Reaction (RT-PCR) 
RT-PCR was carried out for smei-quantitative analysis of the mRNA levels of 
different genes. With equal number of cycles； the band intensity increased , 
proportionally to the amount of mRNA present. 
1000 ng of total RNA was reversely transcribed to complementary DNA (cDNA) 
and PCR was carried out for amplification of target genes. The reverse-transcription 
< 
of mRNA into cDNA was performed by TaqMan Reverse Transcription Reagents 
/ 
(Applied Biosystems, U.S.A.). Taq PCRx DNA Polymerase Reagents (Invitrogen, U.S.A.) 
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were used for PGR. Details of procedures can be referred to Chapter 2. 
Ninjurinl and GAPDH were selected for PGR. The primers of genes were shown 
in the following table. 
Primer set Sense primer, 5'今3' Antisense primer, 5'->3' 
Ninjl TCAAGTACGACCTTAACAACCCG TGAAGATGTTGACTACCACGATG 
GAPDH CAGCCGAGCCACATCG TGAGGCTGTTGTCATACTTCTC 
The PGR products were resolved by gel electrophoresis in which 2% agarose gel 
was pre-stained with ethidium bromide and visualized by a ultra-violet light cabinet 




3.2.2.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of 
protein lysate and Western blotting 
I. Protein extraction 
3 X 10® SA cells and 5 x 10® DX5 cells were seeded on a 60-mm culture dish 
(IWAKI, Japan) for 24 hours to allow adhesion. 48 hours after transient transfection, 
the cells were harvested using Lammeli's solution. The lysates were centrifuged at 
15,000 X g for 7 minutes at 4°C. The supernatants were transferred to a new 
microfuge-tube, added with 2X SDS sampling buffer and boiled for 10 minutes before 
storage at -20°C. 
II. Determination of protein concentration 
The protein concentration of extracted sample was determined by bicinchoninic 
(BCA) assay. The absorbance at 540 nm was measured by a microplate reader , 
(Bio-rad, U.S.A.). Protein concentration of the samples was calculated according to 
the BSA standard curve. Details of ingredients and procedures can be referred to 
chapter 2. 
i 
III. SAS-Polvacrvlamide gel electrophoresis (SDS-PAGE) 
30 |ig of protein from each sample was mixed with IX SDS loading buffer 
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making up to 20 loading mixture. The mixture was loaded onto a 12% SDS-PAGE 
for P-actin and 15% for Ninjurinl (Ninjl), then subjuected to electrophoresis at 200 V 
for 50-60 minutes for protein separation by BIORAD Mini-ROTEAN III Cell system. 
IV. Semi-dry transfer of protein to PVDF membrane 
The Polyvinylidene fluoride (PVDF) membranes were pre-wetted in 100% 
methanol and equilibrated in E-blot buffer. The protein on the . SDS-PAGE was 
transferred to the membrane by Trans-Blot SD Semi-Dry Transfer Cell system with a 
constant current of 0.15 A for 30 minutes. 
V. Enhanced chemiluminescence (ECU detection 
The membrane was incubated with 5% non-fat dry milk in PBS at 4。C overnight 
for blockage. The membrane was probed with primary antibodies for 2 hours and , 
then probed with respective horse-radish peroxidase conjugated secondary 
antibodies for further 2 hours. The primary antibodies used in this study were 
anti-P-actin (Sigma Aldrich Co., U.S.A.) and anti-Ninjurinl (BD Bioscience, U.S.A.). 
After secondary probing, the membrane was washed. The chemiluminscent 
f 
signals of the bands were detected by the ECL Western blotting detection reagent. 
/ 
Details of procedures and purchasing information can be referred to Chapter 2. 
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3.2.2.4 DNA plasmid extraction 
Large scale of DNA plasmid was prepared with NucleoBond Xtra Midi Kit. 
Colonies were picked from the agar plate, and a 100 ml culture of LB medium was 
inoculated by incubating overnight at 37°C at 300 cycles/minute. The cells were 
collected and centrifuged at 4,500 x g for 30 minutes at 4°C. The supernatant was 
discarded and the cell pellet was resuspended completely in 8 ml Resuspension 
Buffer RES with RNase A. The cells were lysed by adding 8 ml Lysis Buffer LYS. The 
NucleoBond Xtra Column and the inserted column filter were equilibrated with 12 ml 
Equilibration Buffer EQU. The suspension was added with 8 ml Neutralization Buffer 
NED and subjected to NucleoBond Xtra Colum filter. The column was allowed to 
empty and washed with 5 ml Equilibration Buffer EQU. The column filter was 
discarded and the column was washed with 8 ml Wash Buffer WASH. The plasmid 
DNA was eluted with 5 ml Elution Buffer. 3.5 ml isopropanol was added to the 
r 
plasmid DNA elution to precipitate the elution plasmid DNA. The mixture was 
allowed to sit for 2 minutes at room temperature and centrifuged at 15,000 x g for 30 
minutes at 4°C. The supernatant was discards. The pellet was washed with 2 ml 70% 
ethanol and centrifuged at 15, 000 x g for 5 minutes at room temperature. The DNA 
pellet was dissolved in IX TE buffer and stored at -20°C. 
i 
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3.2.2.5 Transient transfection 
3 X IQS cells were seeded onto each well in a 6-well microplate (IWAKI； Japan) in 
DMEM medium supplemented with 10% FBS and incubated for 24 hours in a 
humidified incubator with 5% CO2 supplied at 37°C. Before transfection, medium was 
removed and the cells were washed with FBS and PS free plain DMEM medium. 1.5 
ml complete DMEM medium and 0.5 ml freshly prepared DNA-Lipofectamine 2000 
complex were added to each well. The mixture was incubated for 4 hours in a 
humidified incubator with 5% CO2 supplied at 37 °C. After incubation, the 
transfecting medium was removed and replaced by complete DMEM medium. The 
cells were incubated for 48 hours before harvest for further assay. 
DNA-Lipofectamine 2000 complex preparation: 4 \ig pCMV6-AV-GFP-Ninjl or 
pCMV6-XL plasmid was mixed with 250 |il plain medium; 4 \x\ lipofecamine 2000 , 
reagent was mixed with 250 [x\ plain medium. The plasmid mixture and lipofectamine 
mixture were incubated separately for 5 minutes at room temperature. They were 
then mixed and incubated for another 20 minutes at room temperature before 
usage. 
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3.2.2.6 MTT assay 
The viability of cells was measured by MTT assay. 1 x 10^  cells were seeded onto 
each well on a 96-well culture plate (IWAKI) and incubated for 24 hours in a 
humidified incubator with 5% CO2 supplied at 37。C. The cells were then transfected 
with pCMV6-AV-GFP-Ninjl or pCMV6-XL plasmid, and seeded for further 24 hours. 
Appropriate concentrations of Dox were added to the cells and the cells were 
allowed for incubation at 37°C for further 48 hours. 
After 2 days incubation with the anticancer drugs, the cells were treated with 50 
|il of MTT solution (1 mg/ml in PBS) at 37。C for 2 hours and lysed in 150 |il of 
dimethyl sulfoxide (DMSO) at room temperature for 45 minutes. The absorbance of 
each well was measured at 570 nm in microplate reader. The absorbance is directly 
proportional to the survival of cells. The percentage of cell viability was calculated as , 
follows: 
% viability = [OD540 of test sample/OD54o of control] x 100% 
The cell survival was analyzed by Student's t test. 
I 
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3.2.2.7 Quantification of doxorubicin (Dox) uptake by flow cytometry 
3 X IQS cells were seeded onto a 6-well microplate (IWAKI； Japan) and incubated 
for 24 hours in a humidified incubator with 5% CO2 supplied at 37°C before 
transfection. After transfection； the cells were seed for further 48 hours. The medium 
was changed and 10 uM Dox was added to the cells and incubated for 4 hours at 37 
。C. The cells were trypsinized and washed with PBS twice. The samples were then 
analyzed by FACSCanto Flow Cytometer (BD Biosciences, U.S.A.). The signals were 





3.3.1 mRNA expression of Ninjurinl (Ninjl) in SA and DX5 cells 
By microarray (Wang et al； 2009)； it was found that there was 2 fold Ninjurinl 
down-regulation in multidrug resistant human hepatocellular carcinoma (R-HepG2 
cells) than in drug sensitive human hepatocellular carcinoma. Semi-quantitative 
RT-PCR was performed to determine the level of Ninjl in SA and DX5 cells to find out 
if that was also down-regulated in multidrug resistant human uterine sarcoma cells. 
According to the RT-PCR result, there was a significant lower Ninjl expression in 
DX5 cells than SA cells. With the software Image J, the RT-PCR result was statistically 
analyzed by normalizing to a housekeeping gene, GAPDH. It was found that the DX5 
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Figure 3.1 mRNA expression of Ninjurinl (Ninjl) in SA and DX5 cells 
The mRNA transcription level of Ninjurinl in SA and DX5 cells were determined by 
RT-PCR. The DX5 cells showed significant down-regulation in Ninjl gene as shown in 
graph (A). The mRNA expression of Ninjurinl was normalized to a housekeeping gene, 
GAPDH. The expression of gene in DX5 cells were calculated relative to the 
expression in SA cells as shown in graph (B). It was found that the DX5 cells showed 
about 52% 土 0.27 of Ninjurinl compared to SA cell. Each bar was expressed as the 
mean of 3 independent experiments 土 SD. *P<0.05； Student's t test. 
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3.3.2 The protein expression of Ninjurinl (Ninjl) in SA and DX5 cells 
To investigate the expression of Ninjurinl in protein level, Western blotting was 
carried out to show the Ninjurinl expression in SA and DX5 cells. The band intensity 
developed by the enhanced chemiluminescence detection kit is directly proportional 
to the amount of protein present in the sample and the house-keeping protein 
P-actin was used as the internal control for the assay. As shown in Figure 3.2, there 
high Ninjurinl expression in SA cells, whereas there was significantly lower level of 
Ninjurinl expression in DX5 cells. The DX5 cells showed 49.8% of Ninjurinl protein 
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Figure 3.2 The protein expression of Ninjurinl in SA and DX5 cells 
The protein expression level of Ninjurinl in SA and DX5 cells was determined by 
western blotting. The DX5 cells showed significant lower Ninjurinl protein expression 
as shown in graph (A). The protein expression of Ninjurinl was normalized to a 
housekeeping gene, P-actin. The protein expression in DX5 cells were calculated 
relative to the expression in SA cells as shown in graph (B). It was found that the DX5 
cells showed about 49.8% 土 0.07 of Ninjurinl compared to SA cell. Each bar was 
expressed as the mean of 3 independent experiments 土 SD. ***P<0.005, Student's t 
test. 
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3.3.3 Ninjurinl (Ninjl) cDNA transfection in DX5 cells 
As there was a down-regulation of Ninjurinl in DX5 cells； Ninjl cDNA plasmid 
and empty vector control plasmid were transiently transfected into DX5 cells using 
lipofectamine 2000 reagent for over-expression of Ninjl in DX5 cells. The efficiency 
of transfection was determined using RT-PCR. According to the RT-PCR result, there 
was a significant higher Ninjl expression in DX5 cells transfected with Ninjl cDNA 
plasmid than the control and empty vector control DX5 cells. The expression of Ninjl 
in Ninjl-transfected DX5 cells (DX5一Ninjl) was restored to about the same level as 
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Figure 3.3 Agarose gel electrophoresis of RT-PCR of Ninjurinl in SA and DX5 cells 
The mRNA transcription of Ninjurinl in the cell lines were analyzed with RT-PCR for 
ensuring the efficiency of Ninjurinl transient transfection. The result was normalized 





3.3.4 mRNA expression of MDRl in Ninjurinl-transfected DX5 cells (DX5_Ninjl) 
The MDRl gene expression difference between DX5 control {DX5_c), DX5 empty 
vector control (DX5_vc) and DX5_Ninjl cells were analyzed by RT-PCR. After 48 hours 
of transient transfection, the total DNA was extracted from cells and subjected to 
semi-quantitative RT-PCR. 
According to the RT-PCR result； there was a slight decrease in MDRl expression 
in DX5_Ninjl cells than DX5 control cells. With the software Image J, the RT-PCR 
result was statistically analyzed by normalizing to a housekeeping gene, GAPDH. It 
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Figure 3.4 mRNA expression of MDRl in Ninjurinl transfected DX5 cells 
The mRNA transcription of MDRl in the cell lines were analyzed with RT-PCR. The 
result showed a slight decrease in MDRl expression in DX5_Ninjl cell. The result was 
normalized to a house-keeping gene GAPDH. The DX5_Ninjl cell showed 91% 土 0.03 
MDRl expression compared to DX5 control cell. Each bar was expressed as the mean 
of 5 independent experiments 土 SD. 
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3.3.5 P-glycoprotein expression in Ninjurinl-transfected DX5 cells 
As MDRl gene encodes for P-glycoprotein, the change in MDRl gene expression 
might lead to a change in P-glycoprotein after transfection. Therefore, the 
P-Glycoprotein expression difference between DX5 control, DX5 empty vector control 
and DX5一Ninjl transfected cells was analyzed by RT-PCR. After 48 hours of transient 
transfection； the total protein was extracted from cells and subjected to Western 
blotting. 
According to the Western blotting result, there was a decrease in MDRl 
expression in DX5-Ninjl cells than DX5 control cells. With the software Image J, the 
Western blotting result was statistically analyzed by normalizing to a housekeeping 
gene； P-actin. It was found that there was about 26% decrease in P-glycoprotein 
expression in DX5一Ninjl cells. , 
4 
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Figure 3.5 P-glycoprotein expression of M D R l in Ninjurinl-transfected DX5 cells 
The P-glycoprotein (Pgp) expression in the cell lines were analyzed with Western 
blotting. The result showed a decrease in Pgp expression in DX5_Ninjl cells. The 
result was normalized to a house-keeping gene p-actin. The DX5一Ninjl ceils showed 
74.0% 土 0.2 Pgp expression compared to that of the DX5 control cells. Data shown 
was expressed as the mean of 3 independent experiments 土 SD. *P<0.05, Student's t 
test. 
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3.3.6 Cytotoxicity of doxorubicin (Dox) on DX5 control, DX5 vector control and 
DX5_Ninjl cells 
DX5 cells were transiently transfected with Ninjurinl (Ninjl) and cytotoxicity 
test was performed to find out if there was change in cytotoxicity of Dox on DX5 cells 
upon Ninjurinl over-expression. MTT assay was performed to determine the 
dose-response relationship between Dox and the toxicity on the cells. The IC50 of the 
DX5 control cells were 15 \iW\, while that of DX5一Ninjl cells was 10 \xN\. It suggested 
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Figure 3.6 Cytotoxicity of doxorubicin (Dox) on DX5 control and DX5_Ninjl cells 
Cell survival was investigated by MTT assay 48 hours after same concentration of Dox 
f 
treatment on DX5 control and DX5_Ninjl cells. The DX5_Ninjl cells were more 
sensitive to Dox than the DX5 control and DX5 vector control cells. Each point was 
expressed as the mean of 4 independent experiments, each consisted of 4 replicates 
土 SD. •P<0.05, Student's t test. 
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3.3.7 Doxorubicin (Dox) uptake by SA control, DX5 control and DX5_Ninjl cells 
P-glycoprotein is an efflux pump that can extrude Dox from cells. The 
internalized Dox of cells reflects the activity of P-glycoprotein in cells. The cellular 
Dox uptake by SA control, DX5 control and DX5一Ninjl cells were determined by flow 
cytometry. Dox possesses fluorescent property, so its internalization was detected 
directly by the fluorescence intensity through the PE-A channel. 
After treating the SA and DX5 cells with 10 |iM Dox for 4 hours, 99.2% of SA 
control cells and 97.4% of SA vector control cells exhibited internalized Dox, while 
3.18% DX5 control cells, 5.34% DX5 vector control cells and 16.3% DX5一Ninjl cells 
exhibited internalized doxorubicin. The DX5_Ninjl cells showed statistical significant 
increase in Dox uptake compared to DX5 vector control cells. This indicated that the 












































































Figure 3.7 Doxorubicin (Dox) uptake by SA and DX5 cells 
SA and DX5 cells were treated with 10 [xW\ Dox for 4 hours. Cells were harvested and 
washed. The intracellular fluorescent intensity was measured by flow cytometry. In 
graph (A), red, black and green peak corresponded to SA vector control, DX5 vector 
control and DX5_Ninjl cells respectively. The result shown was the representative 
result of 4 independent experiments. Graph (B) showed the mean ± SD of population 
of cells with internalized Dox. SA control cells showed 99.2% ± 0.30o/o and SA vector 
control cells showed 97.4% 土 1.39% Dox internalized; while DX5 control cells showed 
3.18% 土 0.650/0, DX5 vector control cells showed 5.34% 土 0.77o/o and DX5_Ninjl cells 
showed 16.3% 土 4.12% Dox internalized respectively. The DX5一Ninjl cells showed 
significant increase in Dox uptake compared to DX5 vector control cells. *P<0.05, 





Previous microarray result revealed that there was about 2 fold lower Ninjurinl 
transcription level in resistant human hepatocarcinoma cell RHepG2 than in its 
parental drug-sensitive cell line HepG2 (Wang et al； 2009). Consistent result was 
found in human uterine sarcoma cells in this study as shown in figure 3.1 and figure 
3.2. The drug-resistant uterine sarcoma (DX5) cells showed significant lower 
Ninjurinl expression in both mRNA and protein level, both accounting for about 52% 
mRNA expression and 49.8% protein expression of parental SA cell. It should be 
noted that the Dox-resistant R-HepG2 cells and Dox-resistant DX5 cells were derived 
by the same protocol with stepwized increased concentrations of Dox treatment on 
the parental cell lines. 
It was demonstrated that there was up-regulation of MDRl gene and , 
P-glycoprotein in DX5 cells in chapter 2. For combining the previous findings on . 
MDRl and Ninjurinl expression difference in SA and DX5 cells, Ninjurinl was 
over-expressed in DX5 cells by transient transfection and the transfection efficiency 
was ensured as shown in figure 3.3. 
/ 
RT-PCR result showed that Ninjurinl trasnfected DX5 cells (DX5—Ninjl cells) did 
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not show significant difference in MDRl expression level compared to the DX5 
control cells and DX5 vector control cells, regarding figure 3.4. Ninjurinl was also 
overexpressed in SA cells, but no change in MDRl level was detected (Data not 
shown). However, as shown in figure 3.5, DX5_Ninjl cells showed statistically 
significant decrease in P-glycoprotein expression comparing to control. This 
suggested that Ninjurinl might contribute to multidrug resistance by interfering 
P-glycoprotein expression but not involving in the transcription of MDRl gene. 
The MTT assay and doxorubicin uptake assay showed consistent results that 
DX5一Ninjl cells showed higher sensitivity to drug treatment and lower 
P-glycoprotein activity. With higher expression of Ninjurinl, the viability of DX5 cells 
decreased upon doxorubicin treatment of same concentration as the control DX5 
cells. There was a 33.3% decrease in IC50 in DX5 cells with Ninjurinl over-expression. , 
Moveover； the amount of doxorubicin intake in DX5_Ninjl cells were significantly 
higher than that in control DX5 cells. As shown in figure 3.7, there was an obvious 
peak shift in DX5一Ninjl cells. This suggested that Ninjurinl might be involved in 
controlling the intracellular drug concentration through the decreased P-glycoprotein 
( 
expression and activity as one of the mechanisms of lowered multidrug resistance in 
DX5_Ninjl cells. 
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Recent research on Ninjurinl found that Ninjurinl could induce p21 expression 
and induce cellular senescence in human hepatoma cells (Toyama et al. 2004). p21 
was one of the key regulators of senescence which control cell growth (Brown et al, 
1997; Burkhart et al. 1999). Toyama et al. (2004) suggested that Ninjurinl inhibited 
growth of cell by provoking cell cycle arrest. As cellular senescence was considered as 
a powerful tumor suppressive mechanism which limit the proliferative capacity of 
cells (Wynford et al； 1999)； Ninjurinl was suspected to play a role in cancer 
progression if cells were able to overcome Ninjurinl-mediated senescence to grow 
(Toyama et al； 2004). This further supported the results in the present study that 
Ninjurinl might take part in multidrug resistance as the lower Ninjurinl expression in 
DX5 enables it to proliferate and survive from Dox treatment, and thus generate drug 
resistance. On the other hand, the Ninjurinl-overexpressed DX5 cells were more 
sensitive to Dox might be owing to the Ninjurinl-mediated senescence in cells. , 
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3.5 Conclusion 
In summary, the present study demonstrated Ninjurinl was involved in cancer 
cells growth and multidrug resistance. It was revealed that the relationship between 
Ninjurinl and MDRl was related to multidrug resistance: the over-expression of 
Ninjurinl in multidrug resistant human uterine sarcoma cells reversed multidrug 
resistance by reducing the expression and activity of P-glycoprotein and the 










Numerous genes were found closely related to tumorigenesis； especially for 
those involving in controlling cell growth, angiogenesis and metastasis. 
Thrombospondinl (THBSl) was one of the well-studied genes that proven to be 
highly related to tumor progression. 
Thrombospondinl is a 450kd extracellular matrix glycoprotein with multiple 
structural domains and ligand binding sites. Owing to its adhesion ability； it was 
found that thrombospondinl plays a role in metastasis (Yabkowitz et al, 1993). More 
importantly； Thrombospondin was found to take part in suppressing tumor growth 
due to its anti-angiogenesis property. Neovascularization is important in solid tumor 
development. In normal cells, p53 regulates the expression of Thrombospondinl, 
which inhibits the formation of new blood vessels (Dameron et al, 1994; Grossfeld et 
al； 1997). However； both in vitro and in vivo studies also revealed that • 
Thrombospondinl was down regulated and angiogenesis was enhanced in many 
malignant cells (Weinstat-Saslow et al, 1994; Sheibani et al, 1995Tuszynski et al, 




As the major hindrance in chemotherapy, multidrug resistance should also be a 
vital role in tumor progression. However, there is a lack in investigating the 
relationship between Thrombospondinl and multidrug resistance. According to the a 
microarray-based research on transcriptional analysis of doxorubicin-induced 
cytotoxity and resistance in human hepatocellular carcinoma cell line； it was found in 
our laboratory that the transcriptional level of Thrombospondinl was lower in the 
multidrug resistance cell line RHepG2 than its drug sensitive parentakell line HepG2 
(Wang et al； 2009). Moreover, a recent research discovered that Txrl, which is a 
transcriptional regulator of thrombospondinl, was involved in cellular sensitivity to 
texane (Lih et al, 2006). These provoked our interest that Thrombospondinl may also 
involve in the development of multidrug resistance. 
To gain better understanding in the relationship between Thrombospondinl ‘ 
expression and drug sensitivity of cancer cells, the pair of doxorubicin-resistant 
and -sensitive human uterine sarcoma cells (SA and DX5 cells) was used. 
Thrombospondinl expression in these two cell lines was firstly compared. After that, 
Thrombospondinl was over-expressed in doxorubicin-resistant uterine sarcoma cell 
4 
line {DX5 cells) by transient transfection to see whether this caused drug sensitivity 
difference in the DX5 cells. 
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4.2 Materials and Methods 
4.2.1 Materials 
4.2.1.1 Cell lines 
Human uterine sarcoma cell line MES-SA (SA) and Multiple drug resistant cell 
line MES-SA/DX5 were used. The purchase information can be referred to Chapter 2. 
4.2.1.2 Cell culture medium, supplements and buffers 
Fetal bovine serum (FBS) and antibiotics (Penicillin and streptomycin) were 
added to Dulbecco's Modified Eagle's Medium (DMEM) to constitute complete 
medium. Trypsin-EDTA and phosphate-buffered saline (PBS) were used in the 
subculture of cell lines. The purchase information and ingredients can be referred to 
Chapter 2. 
f 
4.2.1.3 Gene expression assay reagents 
I. RNA extraction 
RNase and DNA contaminants were removed with RNase AWAY, which was 
purchased from Molecular BioProducs (U.S.A.). RNA sample was extracted from cells 
t 
with NucleoSpin RNA II total RNA Isolation Kit, which was purchased from 
MACHEREY-NAGEL (Germany). 
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II. Reverse Transcription (RT) 
Reverse transcription was performed with TaqMan Reverse Transcriptase 
Reagents, which was purchased from Applied Biosystems (U.S.A.). 
III. Polymerase chain reaction (PCR) 
Polymerase chain reaction was performed with Taq PCRx DNA Polymerase 
Reagents, and primers for amplification of Ninjl and GAPDH, which were purchased 
from Invitrogen Life Science Technologies Inc. (U.S.A.). 
IV. Agarose gel electrophoresis 
The 2% agarose gel for separation of PCR products was made by dissolving 
UltraPure agarose powder, which was purchased from Invitogen Life Science 
Technologies Inc. (U.S.A.)； and 2 ehidium bromide, which was purchased from , 
Pharmacia Biotech (U.S.A.) (10 mg/ml) in IX TBE buffer, which was purchased from • 
Genesee Scientific Corporation (U.S.A.), containing Tris base, boric acid and EDTA). 
GeneRuler lOObp DNA ladder, which was purchased from Fermentas International 
Inc. (U.S.A.), was used as the DNA marker. 6X sample loading buffer was prepared by 
dissolving 0.25% w/v bromophenol blue and 40% w/v sucrose in deionized distilled 
/ 
water and stored at 4。C. 
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4.2.1.4 Western blotting reagents 
I. Cell ivsis buffer 
The cells were harvested and protein was extracted with Lammeli's solution； 
which was freshly prepared before protein extraction and kept on ice. The 
ingredients and purchase information can be referred to Chapter 2. 
II. Bicinchoninic acid (BCA) assay reagents and Bovine serum albumin standard 
Bicinchoninic acid (BCA) assay was performed by mixing reagent A, which was 
bicinchoninic acid, and reagent B, which was made by dissolving CUSO4 • 5H2O in 
concentration 4% w/v in deionized distilled water. The standards of 0.5-10 \xg/[i\ 
were prepared by dissolving the albumin powder in PBS. The chemicals were 
purchased from Sigma Aldrich Co. (U.S.A.). 
t 
III. 2X sampling buffer and IX loading buffer 
2X sampling buffer and IX loading buffer were added to protein extract before 
western blotting. The preparation ingredients and purchasing information can be 
referred to Chapter 2. 
‘ ( 
IV. Gel setting reagents 
. I l l 
TEMED； Ammonium persulfate (APS)； Acrylamide/bis Solution； 4X Lower gel 
buffer and 4X Upper gel buffer were used for gel setting. The ingredients and 
purchasing information can be referred to Chapter 2. 
V. SDS running buffer 
lOX running buffer was prepared by dissolving 30.3 g Tris Base, 144.0 g Glycine 
and 10.0 g SDS in 1000 ml deionized distilled water. The SDS running buffer was 
diluted into IX before use. 
VI. Electroblot buffer (E-blot buffer) 
E-blot buffer was prepared by mixing 66.7 ml lOX Tris-Glycine of pH 8.3,100 ml 
methanol and 500 ml deionized distilled water. lOX Tris-Glysine was prepared by 
dissolving 30.3 g Tris Base and 144.0 g glycine in IL deionized distilled water. , 
VII. Polyvinylidene fluoride (PVDF) membrane 
PVDF membrane with pore size 0.45 \im was purchased from Millipore 
Corporation (U.S.A.) and cut into size of 5.5 cm x 8.5 cm before use. 
i 
VIII. Phosphate-buffered saline-Tween (PBST) washing buffer 
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PBST was prepared by adding 1 ml Tween 20, which was purchased from USB 
Corporation (U.S.A.), into 1 L IX PBS. 
IX. Blocking solution (5% non-fat milk solution) 
Blocking solution was prepared freshly by dissolving non-fat milk powder 
(Nestle, U.S.A.) in PBS at the concentration 5% w/v. 
X. Antibodies 
Primary antibodies 
Mouse monoclonal anti-P-actin was purchased from Sigma Aldrich Co. (U.S.A.). 
Mouse monoclonal anti- Thrombospondinl was purchased from Thermo Fisher 
Scientific (U.K.). The primary antibodies were stored at -20°C. 
Secondary antibodies , 
Horseradish peroxidase (HRP)-conjugated goat anti-mouse immunoglobulin G • 
(IgG) was purchased from Zymed (U.S.A.) and stored at 4°C. 
XII. Western blotting detection reagent and films 
Enhanced chemiluminescence (ECL) reagents were purchased from GE 
Healthcare (U.K.) and stored at 4°C. Medical X-ray films were purchased from Fujifilm 
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Corporation (Japan) and kept in dark. 
4.2.1.5 Plasmid DNA extraction 
I. Competent Cells 
Competent JM109 cells were prepared following Cohen's Calcium Chloride 
method. Cells were allowed to grow for 16 hours at 37°C. A single colony was picked 
and transferred into 100 ml of LB broth. The culture was incubated for 3 hours at 
37°C in a rotary shaker at 300 cycles per minute. The cells were collected and 
centrifuged at at 3,000 x g for 10 minutes at 4°C. The medium was discarded and the 
pellet was resuspended in 10 ml sterile 0.1 M CaClz. The suspension was stored on 
ice for 30 minutes and centrifuged at 3,000 x g for 10 minutes at 4°C. The 
supernatant was discarded and the pellet was resuspended in 2 ml strerile 0.1 M 
CaClz for each 50 ml original culture. The competent cells were stored at -80°C in ‘ 
aliquots. 
II. Bacterial culture medium 
LB Broth and LB agar, which were purchased from USB, were used for bacterial 
I 
culture. The medium was supplemented with 100 |ig/ml ampicillin. The ampicillin 
powder was purchased from Sigma Aldrich Co. (U.S.A.), it was diluted by deionized 
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water into 100 mg/ml and stored at -20°C. 
III. Plasmid DNA extraction 
cDNA Clones: pCMV6-AV-GFP-THBSl, pCMV6-AV-GFP-Ninjl and pCMV6-XL5 
clones were purchased from OriGene Technologies (U.S.A.). Plasmid DNA was 
extracted from bacterial cells with NucleoBond Xtra Midi kit, which was purchased 
from MACHEREY-NAGEL (Germany). 
4.2.1.6 Transient transfection 
Transfecting agent 
DNA-Lipofecatmine 2000 reagent was purchased from Invitrogen (U.S.A.) and 
stored at4°C. 
f 
4.2.1.7 MTT assay reagents 
I. Methvlthiazoletetrazolium (MTT) 
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide powder was 
purchased from USB Corporation (U.S.A.). 1 mg/ml working solution was prepared by 
I 
dissolving the powder in sterile PBS and stored at 4°C in light exclusive container. 
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II. Dimethyl sulfoxide (DMSO) 






4.2.2.1 Cell Culture 
The cells were culture in 100-mm culture dish with 10 ml DMEM medium or 150 
cm^ tissue culture flask with 25 ml DMEM medium in humidified incubator at 37°C 
supplying 10% CO2. Subculture was done every three or four days when about 
70-80% of the bottom area was covered with cells. Cells were harvested in different 
growth phases for different assays. 
For subculture, the culture medium was removed and the cells were washed 
with pre-warmed PBS. The cells were then trypsinized by incubating the cells with 3 
ml trypsin-EDTA solution at 37°C for 5 minutes. DMEM medium was used to stop 
the trypsinization afterwards and then the cell suspension was centrifuged at 1000 x 
g for 5 minutes. The supernatant was discarded and the cell pallet was re-suspended ‘ 
with DMEM medium. After cell number counting, suitable amount of cells were • 
seeded into a new culture dish or flask with complete medium for culture or different 
assays. 
( 
For long time storage, 10% DMSO was added to the cell suspension with 
complete medium and kept in liquid nitrogen. 
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4.2.2.2 Gene expression essay (RT-PCR) 
I. Total RNA extraction 
3x10^ cells were cultivated on a 35 mm culture dish for 48 hours and harvested 
by trypsinization. Total RNA was extracted with NucleoSpin® RNA II total RNA 
Isolation Kit. Details of procedures can be referred to Chapter 2. 
As for the cells carrying out transfection, 3x10^ cells were cultivated on a 35 mm 
culture dish for 24 hours and subjected for transfection. The cells were allowed to 
grow for further 48 hours before harvest. 
II. Reverse-transcriptase Polvmerase-Chain Reaction (RT-PCR) 
RT-PCR was carried out for smei-quantitative analysis of the mRNA levels of 
different genes. With equal number of cycles, the band intensity increased , 
proportionally to the amount of mRNA present. 
1000 ng of total RNA was reversely transcribed to complementary DNA (cDNA) 
and PCR was carried out for amplification of target genes. The reverse-transcription 
I 
of mRNA into cDNA was performed by TaqMan Reverse Transcription Reagents 
(Applied Biosystems, U.S.A.). Taq PCRx DNA Polymerase Reagents (Invitrogen, U.S.A.) 
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were used for PCR. Details of procedures can be referred to Chapter 2. 
Thrombospondinl and GAPDH were selected for PCR. The primers of genes 
were shown in the following table. 
Primer set Sense primer； 3' Antisense primer, 5'->3' 
THBSl TGCCTGATGACAAGTTCCAAG CCAGAGTGGTCTTTCCGCTC 
GAPDH CAGCCGAGCCACATCG TGAGGCTGTTGTCATACTTCTC 
The PCR products were resolved by gel electrophoresis in which 2% agarose gel 
was pre-stained with ethidium bromide and visualized by a ultra-violet light cabinet 
(Alpha Innotech Corporation； U.S.A.). 
r 
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4.2.2.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of 
protein lysate and Western blotting 
I. Protein extraction 
3 X 106 SA cells and 5 x 10® DX5 cells were seeded on a 60-mm culture dish 
(IWAKI, Japan) for 24 hours to allow adhesion. 48 hours after transient transfection； 
the cells were harvested using Lammeli's solution. The lysates were centrifuged at 
15,000 X g for 7 minutes at 4°C. The supernatants were transferred to a new 
microfuge-tube； added with 2X SDS sampling buffer and boiled for 10 minutes before 
storage at -20°C. 
II. Determination of protein concentration 
The protein concentration of extracted sample was determined by bicinchoninic 
(BCA) assay. The absorbance at 540 nm was measured by a microplate reader ' 
(Bio-rad, U.S.A.). Protein concentration of the samples was calculated according to • 
the BSA standard curve. Details of ingredients and procedures can be referred to 
chapter 2. 
III. SAS-Polvacrvlamide gel electrophoresis (SDS-PAGE) 
30 |ig of protein from each sample was mixed with IX SDS loading buffer 
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making up to 20 \x\ loading mixture. The mixture was loaded onto a 12% SDS-PAGE 
for P-actin and 8% for Thrombospondinl (THBSl), then subjuected to electrophoresis 
at 200 V for 50-60 minutes for protein separation by BIORAD Mini-ROTEAN III Cell 
system. 
IV. Semi-dry transfer of protein to PVDF membrane 
I 
The Polyvinylidene fluoride (PVDF) membranes were pre-wetted in 100% 
methanol and equilibrated in E-blot buffer. The protein on the SDS-PAGE was 
transferred to the membrane by Trans-Blot SD Semi-Dry Transfer Cell system with a 
constant current of 0.15 A for 30 minutes. 
V. Enhanced chemiluminescence (ECL) detection 
The membrane was incubated with 5% non-fat dry milk in PBS at 4°C overnight , 
for blockage. The membrane was probed with primary antibodies for 2 hours and . 
then probed with respective horse-radish peroxidase conjugated secondary 
antibodies for further 2 hours. The primary antibodies used in this study were 




After secondary probing； the membrane was washed. The chemiluminscent 
signals of the bands were detected by the ECL Western blotting detection reagent. 




4.2.2.4 DNA plasmid extraction 
Large scale of DNA plasmid was prepared with NucleoBond Xtra Midi Kit. Details 
of procedures and purchasing information can be referred to Chapter 3. 
4.2.2.5 Transient transfection ‘ 
3 X IQS cells were seeded onto each well in a 6-well microplate (IWAKI； Japan) in 
DMEM medium supplemented with 10% FBS and incubated for 24 hours in a 
humidified incubator with 5% CO2 supplied at 37°C f o r t r ans fec t ion . 1.5 ml complete 
DMEM medium and 0.5 ml freshly prepared DNA-Lipofectamine 2000 complex were 
applied to each well. The mixture was incubated for 4 hours in a humidified 
incubator with 5% CO2 supplied at 37°C. After incubation, the transfecting medium 
was removed and replaced by complete DMEM medium. The cells were incubated 
for 48 hours before harvest for further assay. 
r 
DNA-Lipofectamine 2000 complex preparation: 4 |ig pCMV6-AV-GFP-THSBl or 
pCMV6-XL plasmid was mixed with 250 \x\ plain medium; 4 |il lipofecamine 2000 
reagent was mixed with 250 |il plain medium. The plasmid mixture and lipofectamine 
mixture were incubated separately for 5 minutes at room temperature. They were 
then mixed and incubated for another 20 minutes at room temperature before 
usage. 
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4.2.2.6 MTT assay 
The viability of cells was measured by MTT assay. 1 x lO* cells were seeded onto 
each well on a 96-weII culture plate (IWAKI； Japan) and incubated for 24 hours in a 
humidified incubator with 5% CO2 supplied at 37°C. The cells were then transfected 
with pCMV6-AV-GFP-THBSl or pCMV6-XL plasmid, and seeded for further 24 hours. 
Appropriate concentrations of Doxorubicin (Dox) was added to the cells and the cells 
were allowed for incubation at 37°C for further 48 hours. 
After 2 days incubation with the anticancer drugs, the cells were treated with 50 
|il of MTT solution (1 mg/ml in PBS) at 37°C for 2 hours and lysed in 150 |il of 
dimethyl sulfoxide (DMSO) at room temperature for 45 minutes. The absorbance of 
each well was measured at 570 nm in microplate reader. The absorbance is directly 
proportional to the survival of cells. The percentage of cell viability was calculated as . 
follows: 
% viability = [OD540 of test sample/OD54o of control] x 100% 
The cell survival was analyzed by Student's t test. 
t 
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4.2.2.7 Quantification of doxorubicin uptake by flow cytometry 
3 X 10^  cells were seeded onto a 6-well microplate (IWAKI, Japan) and incubated 
for 24 hours in a humidified incubator with 5% CO2 supplied at 37°C before 
transfection. After transfection, the cells were seed for further 48 hours. The medium 
was changed and 10 uM Dox was added to the cells and incubated for 4 hours at 37 
。C. The cells were trypsinized and washed with PBS twice. The samples were then 
analyzed by FACSCanto Flow Cytometer (BD Biosciences； U.S.A.). The signals were 





4.3.1 mRNA expression of Thrombospondinl (THBSl) in SA and DX5 cells 
By microarray, it was found that there was significant difference in 
Thrombospondinl in multidrug resistant human hepatocellular carcinoma (R-HepG2) 
than in drug sensitive human hepatocellular carcinoma. (Wang et al； 2009) 
Semi-quantitative RT-PCR was performed to determine the level of THBSl in SA and 
DX5 cells to find out if that was also down-regulated in multidrug, resistant human 
uterine sarcoma cells. 
According to the RT-PCR result, there was a significant lower THBSl expression 
in DX5 cells than that of SA cells. With the software Image J, the RT-PCR result was 
statistically analyzed by normalizing to a housekeeping gene, GAPDH. It was found 
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Figure 4.1 mRNA expression of Thrombospondinl (THBSl) in SA and DX5 cells 
The mRNA transcription level of Thrombospondinl in SA and DX5 cells were 
determined by RT-PCR. The DX5 cells showed significant down-regulation in THBSl 
gene as shown in graph (A). The mRNA expression of Thrombospondinl was 
normalized to a housekeeping gene, GAPDH. The expression of gene in DX5 cells was 
calculated relative to the expression in SA cells as shown in graph (B). It was found 
that the DX5 cells showed about 39% 土 0.33 of Thorombospondinl compared to that 
of SA cells. Each bar was expressed as the mean 土 SD of 3 independent experiments. 
*P<0.05, Student's t test. 
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4.3.2 The protein expression of Thrombospondinl (THBSl) in SA and DX5 cells 
To investigate the expression of Thrombospondinl in protein level, Western 
blotting was carried out to show the Thrombospondinl expression in SA and DX5 
cells. The band intensity developed by the enhanced chemiluminescence detection 
kit is directly proportional to the amount of protein present in the sample and the 
house-keeping protein P-actin was used as the internal control for the assay. As 
shown in Figure 4.2； there was high Thrombospondinl expression in SA cells, 
whereas there was significantly lower level of Ninjurinl expression in DX5 cells. The 
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Figure 4.2 The protein expression of Thrombospondinl in SA and DX5 cells 
The protein expression level of Thrombospondinl in SA and DX5 cells was 
determined by Western blotting. The DX5 cells showed significant lower THBSl 
protein expression as shown in graph (A). The protein expression of Ninjurinl was 
normalized to a housekeeping gene, P-actin. The protein expression in DX5 cells was 
calculated relative to the expression in SA cells as shown in graph (B). It was found 
that the DX5 cells showed about 37.7% 土 0.14 of THBSl compared to that of SA cells. 
Each bar was expressed as the mean of 3 independent experiments 土 SD. •**P<0.005, 
Student's t test. 
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4.3.3 Thrombospondinl (THBSl) cDNA transfection in DX5 cells 
As there was down-regulation of Thrombospondinl in DX5 cells, THBSl cDNA 
plasmid and empty vector control plasmid were transiently transfected into DX5 cells 
using lipofectamine 2000 reagent for over-expression of THBSl in DX5 cells. The 
efficiency of transfection was determined using RT-PCR. According to the RT-PCR 
result, there was a significant higher THBSl expression in DX5 cells transfected with 
THBSl cDNA plasmid than the control and empty vector control DX5 cells. The 
expression of THBSl in THBSl- transfected DX5 cells (DX5一THBSl) was restored to 
about the same level as that in SA cell. This ensured successful transfection of THBSl 
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Figure 4.3 Agarose gel electrophoresis of RT-PCR of Thrombospondinl in SA and 
DX5 cells 
The mRNA transcription of Thrombospondinl in the cell lines were analyzed with 
RT-PCR for ensuring the efficiency of Thrombospondinl transient transfection. The 
result was normalized to a house-keeping gene GAPDH. Data shown was 
representative of 4 independent experiments. 
f 
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4.3.4 mRNA expression of MDRl in Thrombospondinl-transfected DX5 cells 
{DX5_THBS1) 
The MDRl gene expression difference between DX5 control (DX5_c), DX5 empty 
vector control (DX5_vc) and DX5_THBS1 cells were analyzed by RT-PCR. After 48 
hours of transient transfection, the total DNA was extracted from cells and subjected 
to semi-quantitative RT-PCR. 
According to the RT-PCR result, there was a significant decrease in MDRl 
expression in DX5_THBS1 cells than DX5 control cells. With the software Image J, the 
RT-PCR result was statistically analyzed by normalizing to a housekeeping gene, 
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Figure 4.4 mRNA expression of M D R l in Thrombospondinl transfected DX5 cells 
The mRNA transcription of MDRl in the cell lines were analyzed with RT-PCR. The 
result showed a significant decrease in MDRl expression in DX5_THBS1 cells. The 
result was normalized to a house-keeping gene GAPDH. The DX5一丁HBSl cells showed 
62.8% 土 0.17 MDRl expression compared to DX5 control cells. Each bar was 
expressed as the mean of 5 independent experiments 土 SD. *P<0.05, Student's t test. 
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4.3.5 P-glycoprotein expression in Thrombospondinl-transfected DX5 cells 
As MDRl gene encodes for P-glycoprotein, the change in MDRl gene expression 
might lead to a change in P-glycoprotein after transfection. Therefore, the 
P-Glycoprotein expression difference between DX5 control, DX5 empty vector control 
and DX5一 THBSl transfected cells was analyzed by RT-PCR. After 48 hours of 
transient transfection, the total protein was extracted from cells and subjected to 
Western blotting. 
According to the Western blotting result, there was a significant decrease in 
MDRl expression in DX5-THBS1 cells than DX5 control cells. With the software Image 
J； the Western blotting result was statistically analyzed by normalizing to a 
housekeeping gene, P-actin. It was found that there was about 54.7% decrease in 
P-glycoprotein expression in DX5_THBSl cells. , 
I 
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Figure 4.5 P-glycoprotein expression of MDRl in Thrombospondinl-transfected 
DX5 cells 
The P-glycoprotein (Pgp) expression in the cell lines were analyzed with Western 
blotting. The result showed a significant decrease in Pgp expression in DX5一THBSl 
cells. The result was normalized to a house-keeping gene P-actin. The DX5一THBSl 
cells showed 45.3% ± 20 Pgp expression compared to that of the DX5 control cells. 
Data shown was expressed as the mean of 3 independent experiments 土 SD. *P<0.05, 
Student's t test. 
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4.3.6 Cytotoxicity of doxorubicin on DX5 control, DX5 vector control and DX5一THBSl 
cells 
DX5 cells was transiently transfected with Thrombospondinl (THBSl) and 
cytotoxicity test was performed to find out if there was change in cytotoxicity of Dox 
on DX5 cells upon Thrombospondinl over-expression. MTT assay was performed to 
determine the dose-response relationship between Dox and the toxicity on the cells. 
The IC50 of the DX5 control cells were 15 |iM； while that of DX5_NJnjl cells was 7.5 
I^ M. It suggested that upon transfection with Thrombospondinl, the DX5 cells were 
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Figure 4.6 Cytotoxicity of doxorubicin (Dox) on DX5 control and DX5一THBSl cells 
Cell survival was investigated by MTT assay 48 hours after same concentration of Dox 
treatment on DX5 control and DX5_THBS1 cells. The DX5一THBSl cells were more 
sensitive to Dox than the DX5 control and DX5 vector control cells. Each point was 
expressed as the mean of 4 independent experiments, each consisted of 4 replicates 
土 SD. *P<0.05, Student t test 
f 
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4.3.7 Doxorubicin (Dox) uptake by SA control, DX5 control and DX5_ TH BS1 cells 
P-glycoprotein is an efflux pump that can extrude Dox from cells. The 
internalized Dox of cells reflects the activity of P-glycoprotein in cells. The cellular 
Dox uptake by SA control, DX5 control and DX5_THBS1 cells were determined by flow 
cytometry. Dox possesses fluorescent property, so the extent of its internalization 
was detected directly by the fluorescence intensity through the PE-A channel. 
After treating the SA and DX5 cells with 10 ~M Dox for 4 hours, 99.2% of SA 
control cells and 97.4% of SA vector control cells showed internalized Dox, while 
3.18% DX5 control cells, 5.34% DX5 vector control cells and 37.8% DX5_THBS1 cells 
show internalized Dox. The DX5_THBS1 showed statistical significant increase in Dbx 
uptake compared to DX5 vector control cells. This indicated that the P-glycoprotein 
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Figure 4.7 Doxorubicin (Dox) uptake by SA and DXS cells 
SA and DX5 cells were treated with 10 J..lM Dox for 4 hours. Cells were harvested and 
washed. The intracellular fluorescent intensity was measured by flow cytometry. In 
graph (A), red, black and purple peak corresponded to SA vector control, DX5 vector 
control and DX5_ THBS1 cells respectively. The result shown was the representative 
result of 4 independent experiments. Graph (B) showed the mean ± SD of population 
of cells with internalized ± SD. SA control cells showed 99.2% ± 0.30% and SA vector 
control cells showed 97.4% ± 1.39% Dox internalized; while DX5 control cells showed 
3.18% ± 0.65%, DX5 vector control cells showed 5.34% ± 0.77% and DX5_THBS1 cells 
showed 37.8% ± 6.79% Dox internalized. The DX5_THBSl cells showed significant 




Loss of Thrombospondinl was commonly found in advanced tumor and a 
number of underlying mechanisms regulating the transcription were found. Many 
transcription factors such as E2F-1 and C-Jun were found directly related to the 
transcription of thrombospondinl (Dejong et al； 1999; Ji et al； 2010). Regarding 
epigenetics, it was found that the promoter region of Thrombospondinl gene was 
hypermethylated in many cancer cells, such that the expression of thrombospondinl 
was suppressed and tumor progression was enhanced (Qing et a I, 1999; Yang et a I, 
2003). 
Previous microarray result revealed that there was lower Thrombospondinl 
transcription level in resistant human hepatocarcinoma cell line RHepG2 than that in 
its parental drug-sensitive cell line HepG2. By RT-PCR and Western blotting as shown ‘ 
in figure 4.1 and figure 4.2, it was found that the drug-resistant human uterine . 
sarcoma cells (DX5) showed significant lower Thrombospondinl expression in both 
transcription and translation level, which accounting for about 39% mRNA expression 
and 37.7% protein expression of that of the parental SA cells. Consistent result was 
- < 
demonstrated in human uterine sarcoma cells in this study. 
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Previously it was demonstrated that there was up-regulation of MDRl gene and 
P-glycoprotein in DX5 cells as shown in chapter 2. To investigate the relationship 
between Thrombospondinl and MDRl, Thrombospondinl was over-expressed in 
DX5 cells by transient transfection and the transfection efficiency was ensured as 
shown in figure 4.3. 
To our interest, there was a significant reduction in MDRl and P-glycoprotein 
expression level in Thrombospondinl transfected DX5 cells (DX5一THBSl cells) 
compared to the DX5 control and DX5 vector control cells. Upon Thrombospondinl 
over-expression, there was about 37.2% reduction in MDRl expression as shown in 
figure 4.4; while there was about 54.7% decrease in P-glycoprotein expression. This 
finding suggested that Thrombospondinl may be involved in the multidrug 
resistance by directly regulating the transcription and translation of MDRl and ‘ 
P-glycoprotein. Overexpression of Thrombospondinl was also performed in SA cells. 
According to the RT-PCR result； there was no observable change in the MDRl level 
after Thrombospondinl overexpression. This may due to the high intrinsic 
Thrombospondinl level and low intrinsic MDRl level in the SA cells, that the 
< 
percentage change of Thrombospondinl level in SA cells was not high enough to 
cause obvious change in MDRl. 
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Consistent results were shown in the MTT assay and doxorubicin (Dox) uptake 
assay. According to the MTT assay investigating the cytotoxity of Dox on DX5 cells, 
DX5一THBSl showed higher sensitivity to drug treatment. With higher expression of 
Thrombospondinl, the viability of DX5 cells decreased upon Dox treatment of same 
concentration as the control DX5 cells. There was a 50% reduction in IC50 in DX5 cells 
with Thrombospondinl over-expression. The DX5 control and DX5一THBSl cells 
showed more obvious difference in cell viability in higher concentration of Dox 
treatment as shown in figure 4.6. As for Dox uptake assay, the amount of Dox intake 
in DX5一THBSl cells was significantly higher than that in control DX5 cells. As shown 
in figure 4.7, there was an obvious peak shift in DX5一THBSl cells. This suggested that 
Thrombospondinl involved in controlling the intracellular Dox concentration through 
the down-regulating P-glycoprotein expression and activity. 
f 
Previous studies demonstrated that both Thrombospondinl and MDRl • 
transcription were regulated by the p53 family members (Dameron et al, 1994; 
Johnson et al, 2005). It was undoubted that p53 played a role in linking 
thrombospondinl and MDRl leading to multidrug resistance (MDR). However, the 
present study discovered that Thrombospondinl played a direct role in regulating 
the expression of MDRl. Thrombospondinl may regulate the expression of MDRl by 
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direct hinder of the promoter region of the MDRl gene; or interact with the 
transcription factors that induces the expression of MDRl such as NF-Y ,SP1, NF-B； 
etc. (Rohiff et al, 1998; Bentires-Alj et al, 2003; Okamura et al, 2004). The direct 
relationship between Thrombospondinl and MDRl in the present study was a novel 






The above findings demonstrated a promising result that Thrombospondinl not 
only involves in tumorigenesis but also multidrug resistance. The relationship 
between Thrombospondinl and MDRl was revealed: The down-regulation of 
Thrombospondinl enabled up-regulation of MDRl and thus led to MDR in human 
uterine sarcoma cells. This could be reversed by the over-expression of 
Thrombospondinl, which down-regulated the expression of P-glycoprotein in both 
transcription and translation level. The activity of P-glycoprotein was then reduced 







According to the World Health Organization (WHO), cancer is one of the major 
leading causes of death worldwide. It is more worrying that deaths from cancer are 
rising continuously with an estimated 12 million deaths in 2030. The ultimate goal of 
cancer treatment is to remove cancer cells completely with minimal damage to the 
normal cells. A lot of cancer therapies have been developed, but chemotherapy 
remains the most effective and commonly used method. Chemotherapy involves the 
administration of cytotoxic drugs that kill the rapidly growing cancer cells. However, 
the prolonged use of drugs leads to the development of multidrug resistance (MDR), 
which becomes the major obstacles in cancer treatment. To increase the 
effectiveness of chemotherapy, a lot of research has been done on revealing the 
genes and mechanisms concerning MDR. In this study, two genes, Ninjurinl and 
Thrombospondinl, were analyzed and their novel relationship with MDR was 
studied. , 
5.1 Doxorubicin induced multidrug resistance in human uterine sarcoma cells via 
upregulation of P-glycoprotein 
Researches on MDR relating genes have disclosed many mechanisms leading to 
4 
MDR. In the present study； we analyzed the gene expression difference between Dox 
sensitive human uterine sarcoma SA cells and Dox resistant DX5 cells. It was found 
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that there was only upregulation in MDRl gene among the MDR related genes, and 
the over-expression of P-glycoprotein in DX5 cells led to lower uptake of Dox and rate 
of apoptosis. 
The culturing the Dox resistant DX5 cells required supplement of 1 |iM Dox for 
the maintenance of resistance property of it. It was interestingly found that the IC50 
of DX5 cells increased in the older passage of cells. The above result collectively 
suggested that Dox led to MDR through up-regulation of MDRl and its protein 
produced； namely P-glycoprotein. 
5.2 The down-regulation of Ninjurinl in human uterine sarcoma cells contributed 
to multidrug resistance 
Ninjurinl is a gene responsible for adhesion due to its adhesion motif. Research , 
has demonstrated that It takes part in inflammatory response, tissue remodeling and . 
central nervous system development. However, there is little study on Ninjurinl in 
malignancy. Therefore, the role of Ninjurinl in cancer development remains unclear, 
let alone its role in multidrug resistance. 
( 
In the present study, it was demonstrated that there was down-regulation of 
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Ninjurinl in the Dox resistant human uterine sarcoma cells (0X5) both in the mRNA 
and in the protein expression level. When Ninjurinl cDNA was introduced into DX5 
cells by transient transfection, the Ninjurinl expression level was restored. It was 
found that with Ninjurinl over-expression, the expression of P-glycoprotein in DX5 
cells decreased. Moreover, there was higher level of Dox internalization in the cells 
and higher sensitivity of the cells towards Dox treatment after Ninjurinl 
over-expression. The above results demonstrated that Ninjurinl take part in 
multidrug resistance of the DX5 cells. 
The present study presented a novel view that Ninjurinl was involved in 
development and multidrug resistance of human uterine sarcoma. However, this only 
suggested the basic relationship between Ninjurinl and this cancer or multidrug 
resistance. More work has to be done on revealing the mechanism on how Ninjurinl , 
is related to multidrug resistance or cancer development in human uterine sarcoma • 
or even other types of human cancers. 
First of all； it is of importance to find out why Ninjurinl is down-regulated in the 
‘ f 
resistant human uterine sarcoma cell line. The promoter region of Ninjurinl gene 
could be investigated to see if it is epigenetically silent; or the transcription factor 
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regarding Ninjurinl could be investigated to see if they were down-regulated and led 
to lower transcription level of Ninjurinl. Moreover； the role of Ninjurinl in 
controlling the translation and activity of P-glycoprotein should also be looked into to 
gain thorough understanding on how Ninjurinl was related to multidrug resistance. 
As both Ninjurinl and P-glycoprotein are membrane protein, Ninjurinl may affect 
the activity of P-glycorprotein in the membrane level. The pumping activity of 
P-glycoprotein could be measured so as to find out if Ninjurinl cause change in the 
pumping activity of P-glycoprotein directly. Finally, as the present study stated a 
promising role of Ninjurinl in human uterine sarcoma, it would be of great 
significance in investigating if it was related to the progression of this cancer or 
probable other cancers or how it was involved in cancer development. Regarding its 
adhesion property, Ninjurinl may also contribute to cancer aggressiveness as it may 
help metastasis. , 
Collectively, it was demonstrated that Ninjurinl was involved in multidrug 
resistance by regulating the expression and activity of P-glycorprotein in human 
uterine sarcoma cell lines, and this provides a novel view of Ninjurinl in multidrug 
I 
resistance and development of this cancer that many future work can be carried on. 
. 150 
5.3 The down-regulation of Thrombospondinl in human uterine sarcoma cells 
contributed to multidrug resistance 
Unlike Ninjurinl； the role of Thrombospondinl in tumorigenesis has been 
well-characterized. Thrombospondinl is regarded as a tumor suppressor gene 
because of its anti-angiogenesis property. However, there is limited research relating 
thrombospondinl and multidrug resistance, which is a great topic in cancer 
treatment. 
In this study, it was demonstrated that there was down-regulation of 
Thrombospondinl in the Dox resistant human uterine sarcoma cells (DX5) both in 
the mRNA and in the protein expression level. When Thrombospondinl cDNA was 
introduced into DX5 cell by transient transfection to restore the Thrombospondinl 
expression level, it was found there is down-regulation in the MDRl mRNA and ‘ 
P-glycoprotein level in DX5 cell. Hence, there was higher level of Dox uptake in the . 
cells and higher drug sensitivity of DX5 cells towards Dox treatment after 
Thrombospondinl over-expression. The above results demonstrated that 




As the present study suggest a promising role of Thrombospondinl in multidrug 
resistance, it is important to further work on it so as to reveal how it controls the 
expression of MDRl in human uterine sarcoma cell lines or probable other human 
cancer cell lines. 
First of all； it is important to confirm the reason of lower Thrombospondinl 
expression in the resistant DX5 cells. Research has demonstrated that there is 
hypermethylation in the promoter region of Thrombospondinl in hepatocellular 
carcinomas, leading to its lower expression in malignant cells (Li et al, 1999). This 
may also be the reason why Thrombospondinl is down-regulated in DX5 cells. 
Moreover； as the over-expression of Thrombospondinl directly led to the 
down-regulation of MDRl in mRNA level, the way in which Thrombospondinl 
controls the expression of MDRl in DX5 cells should also be investigated. ‘ 
Dual-Luciferase reporter assay could be done to find if Thrombospondinl bound . 
directly to the promoter region of MDRl and suppressed the expression of MDRl 
gene. Besides hindering the transcription of MDRl directly on its own, 
Thrombospondinl may also control the mRNA level of MDRl by suppressing the 
i 
transcription factor of MDRl. Much work has to be done to control the mechanism 
of controlling MDRl expression by Thrombospondinl in DX5 cells or probable other 
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human cancer cell lines. 
In conclusion, it was found that Thrombospondinl was involved in multidrug 
resistance in human uterine sarcoma cell lines by regulating the expression of MDRl 
and activity of P-glycorprotein； and this provides a promising view of 
Thrombospondinl in multidrug resistance and much future work should be carried 
on. 
5.4 Conclusion and Future Perspective 
RT-PCR result in the present study and previous research suggested that 
prolonged Dox treatment led to over-expression of MDRl in human uterine sarcoma 
cells, which led to the development of multidrug resistance. Ninjurinl and 
Thrombospondinl were also found to be down-regulated in the Dox-resistant human ‘ 
uterine sarcoma (DX5) cell by RT-PCR and Western blotting. More work could be • 
done to find if the treatment of Dox caused the down-regulation of Ninjl and THBSl 
in human uterine sarcoma cell lines and the mechanisms underlying should be 
worked out. To investigate if the intracellular Doxorubicin level affects MDRl 
I 
expression； sub-optimal Doxorubicin level could be used to treat SA cells and RT-PCR 
should be done to find out if there was gene expression difference in Ninjurinl 
. 1 5 3 
and/or Thrombospondinl level. Moreover, as previous study has demonstrated that 
Doxorubicin led to MDRl up-regulation through the FOXO family, microarray could be 
done to compare the gene expression difference between the SA and DX5 cells and 
see if there was also gene expression difference relating to the FOXO pathway which 
may suggest a further step to understand the relationship between Ninjurinl and 
MDRl, and/or Thrombospondinl and MDRl. 
This study suggested a promising result that Ninjurinl and Thrombospondinl 
were involved in multidrug resistance in human uterine sarcoma cell lines by 
regulating the expression of MDRl and/or the activity of P-glycoprotein. This 
provides a novel view concerning multidrug resistance that these two genes may also 
be developed into gene therapy target in human uterine sarcoma or probable other 
human cancers. , 
The present study contributed only a small part in understanding the complex 
network in controlling multidrug resistance, a lot of work has to be carried on in 
dealing with multidrug resistance in human uterine sarcoma and other human 
‘ t 
cancers, the major obstacle in chemotherapy. 
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